

Review article:

Cutting Edge Science

The Emphatic Role of Mitogen-Activated Protein Kinases (MAPKs) in the Cellular Mechanisms Mediating Alzheimer's Disease

John J. Haddad ^{a, b, c, d} *

^a Severinghaus-Radiometer Research Laboratories, Department of Anesthesia and Perioperative Care, Faculty of Medicine, University of California, San Francisco, California, USA; ^b Molecular Signaling Research Group, Division of Biological Sciences, Departments of Biology and Biomedical Sciences, Faculty of Arts and Sciences, Lebanese International University, Beirut, Lebanon; ^c Department of Biology, Faculty of Sciences, University of Balamand, Balamand, Tripoli, Lebanon; ^d Department of Clinical Laboratory Sciences, Faculty of Health Sciences, University of Balamand, Aschrafieh, St Georges Hospital Complex, Beirut, Lebanon. *Corresponding author's address: Dr. John J. Haddad, Departments of Biology and Biomedical Sciences, Faculty of Arts and Sciences, Lebanese International University, Beirut 14-6404, Lebanon. Email address: john.haddad@yahoo.co.uk. *Retrospect affiliation:* Severinghaus-Radiometer Research Laboratories, Department of Anesthesia & Perioperative Care, Faculty of Medicine, University of California, San Francisco, CA, USA.

ABSTRACT

Alzheimer's disease (AD) is a neurogenetic condition that affects the processes via which the brain functions. Major observable hallmarks of AD are accumulated clusters of proteins in the brain. These clusters, termed neurofibrillary tangles (NFT), resemble pairs of threads wound around each other in a helix fashion accumulating within neurons. These tangles consist of a protein called *Tau*, which binds to tubulin, thus forming microtubules. Unlike NFTs, deposits of amyloid precursor protein (β -APP) gather in the spaces between nerve cells. The nearby neurons often look swollen and deformed, and the clusters of protein are usually accompanied by reactive inflammatory cells, microglia, which are part of the brain's immune system responsible for degrading and removing damaged neurons or plaques. Since phosphorylation/dephosphorylation mechanisms are crucial in the regulation of *Tau* and β -APP, a superfamily of mitogen-activated protein kinases (MAPKs) has recently emerged as key regulators of the formation of plaques, eventually leading to dementia and AD. The complex molecular interactions between MAPKs and proteins (plaques) associated with the evolution of AD form a cornerstone in the knowledge of a still burgeoning field of neurodegenerative diseases and ageing. This review overviews current understanding of the molecular pathways related to MAPKs and their role in the development of AD and, possibly, dementia. MAPKs, therefore, may constitute a neurogenetic, therapeutic target for the diagnosis and evolution of a preventative medical strategy for early detection, and likely treatment, of Alzheimer's.

Keywords: Alzheimer's; β -Amyloid precursor protein; Dementia; MAPK; Neurodegeneration; Neurofibrillary tangles; *Tau*.

Contents

1. Introduction

2.

3. MAPK signaling modules and pathways: A network overview

MAPK signaling pathways as viewed through their identification and bifurcations

MAPK signaling as viewed through receptor and non-receptor coupled cofactors

4. Alzheimer's disease: An overwhelming etiological condition or a maneuverable syndrome?

5. The role of MAPKs in Alzheimer's: Mechanisms and possible therapeutic targets

Paired helical filaments and Tau phosphorylation

Tau phosphorylation and MAPK inhibition

Tau structural analysis and MAPK-related protein phosphorylation

Tau/ β -APP-mediated phosphorylation mechanisms and MAPK regulation

Redox/oxidative mechanisms and MAPK-mediated Tau phosphorylation

Inflammatory mediators and MAPK-mediated Tau phosphorylation

6. Summary, conclusions and future prospects

Acknowledgments

References

1. Introduction

The syndrome of dementia, which represents a progressive deterioration in intellectual abilities, can be so severe to an extent it may interfere with the person's usual social and occupational functioning (Burnham, 1988; Floyd, 1999; Harper and LoGrasso, 2001; Peel, 2004; Samanta et al., 2006; Wurtman, 1985). An estimated 5-10 % of the US adult population (ages 65 and older) is affected by a dementing disorder, and the incidence doubles almost every 5 years among people falling within this age group (Drachman, 2006; Erickson, 1991; Sellcoe, 1991; Runden et al., 1998).

Alzheimer's disease (AD) is the most common form of dementia, especially in the US; it and related dementias affect at least 2 million, and possibly as many as 4 million, residents. Despite its prevalence, dementia often goes unrecognized or is misdiagnosed in its early stages (Beardsley, 1993; Beardsley, 1995; Jellinger, 2006; Zhu et al., 2001a). Some disorders that result in dementia are 'reversible' or 'potentially reversible,' which means that they can be treated effectively to restore normal or nearly normal intellectual function (Giannakopoulos, et al., 2007; St George-Hyslop, 2000).

Among the most frequent reversible causes of dementia are depressions, alcohol abuse and drug toxicity (Suram et al., 2006). In elderly persons, drug use — particularly drug interactions caused by 'poly-pharmacy' (simultaneous use of multiple drugs) — is a common cause of cognitive decline (Uhlhaas and Singer, 2006). Depression also is an under-diagnosed condition in this population (Erickson, 1991). However, the majority of dementias, including AD, are considered non-reversible. Even for these conditions, correct diagnosis of the problem in its early stages can be beneficial (Martindale, 2002). In addition, many of the non-reversible dementias include symptoms such as incontinence, wandering and depression that can be treated effectively (Dickey and Petrucelli, 2006; Wurtman, 1985).

The underlying factors contributing to the evolution and perpetuation of AD remain largely obscure (Martindale, 2002; St. George-Hyslop, 2000). Biomedical researchers have devised psychological screening tests to try to identify people in the early

stages of AD. Apart from memory loss, there are nine other warning signs — among them difficulty performing familiar tasks, problems with language, such as remembering words, disorientation in time and space, and changes in personality. Susceptible people appear to have a greater sensitivity to the drug tropicamide, which is ordinarily used to dilate the pupils in a routine eye exam (Martindale, 2002; Wurtman, 1985). But for the most part, diagnosis has been a process of elimination. Microscopic views, for instance, have revealed a loss of nerve cells in certain regions of the brain, such as the hippocampus, a center for memory, and the cerebral cortex, which is involved in reasoning, memory, language and other important thought processes (Morgan, 2006; St George-Hyslop, 2000).

The other more directly observable hallmarks of AD are clusters of proteins that accumulate in the brain. These accumulations usually occur in two forms: those found inside nerve cells and those found between cells. The clusters in the interior are called neurofibrillary tangles (NFTs) and they resemble pairs of threads wound around each other in a form of a helix. Biochemical analyses showed that these tangles consist of a protein called *Tau* (Anderton et al., 2001; Dickey and Petrucelli, 2006). *Tau* is significant because it binds to a protein named tubulin, which in turn forms structures known as microtubules (microtubules are crucially important in the structural framework of living cells). Like the girders and pillars of buildings, they run through cells, thereby imparting support and shape. Microtubules also provide routes along which nutrients, other molecules and cellular components such as vesicles and mitochondria move through cells (Johnson, 2006; Martindale, 2002; St George-Hyslop, 2000).

Unlike NFTs, deposits of amyloid protein gather in the spaces between nerve cells. The nearby neurons often look swollen and deformed, and the clusters of protein — sometimes called senile or amyloid plaques — are usually accompanied by reactive inflammatory cells called microglia, which are part of the brain's natural immune system that help degrade and remove damaged neurons or perhaps the plaques themselves (Haddad 2002e; Martindale, 2002). It is unclear, however, whether the neurons in or near these plaques function normally, because the density of plaques is only weakly correlated with the severity of dementia.

Further, such plaques are present in most elderly people. Nevertheless, their extensive presence in the hippocampus and the cerebral cortex is specific to AD and they appear long before NFTs do (Higuchi et al., 2005).

Intensive efforts to isolate the ingredients of these plaques culminated with the discovery that a principal component was a peptide made up of 40-42 amino acids (St George-Hyslop, 2000). The sequencing of the gene for the longer protein from which this peptide originates quickly followed this identification of what is now termed the β -amyloid peptide: the β -amyloid precursor protein (β -APP). Although the precise biological role of normal β -APP molecules remains obscure, it is currently known that many kinds of cells and tissues produce β -APP and that it can be between 695 and 770 amino acids long (Martindale, 2002). The protein runs through the outer cell membrane, with a short piece jutting into the cell and a longer piece sticking into the extracellular space. The β -amyloid peptide, for its part, is snipped out of the section of β -APP that spans the cell membrane. β -APP is cut in one of two ways: in one process, the protein is first cleaved by an enzyme called α -secretase; it is then cut by another putative enzyme, γ -secretase. Together these cuts produce a harmless peptide fragment called p3 (St George-Hyslop, 2000). The second way in which β -APP is cleaved is another two-step process, one that is not always so harmless. First, an enzyme called β -secretase clips the protein; one of the resulting pieces, called C99- β -APP fragment, is then snipped by γ -secretase and the β -amyloid peptide is born (Dickey and Petrucelli, 2006).

At the molecular level, the biochemical, molecular, genetic, epidemiological and clinical discoveries have significantly advanced our understanding of the mechanisms underlying the evolution of AD and made it increasingly likely that, in the years to come, useful therapeutic treatments will be proposed. Some of these will probably come from the recent insights into the mis-processing or phosphorylation of *Tau*, a key mechanism in the regulation of Alzheimer's (Blennow et al., 2006; St George-Hyslop, 2000). Indeed, the insights into β -APP and β -amyloid peptide are already fueling treatment research. For instance, some investigators are designing compounds that will block the ability of either β - or γ -secretase enzymes to

cut β -APP, thus preventing the creation of the damaging β -amyloid peptide. Others are seeking to alleviate the peptide's effects once it has been created. Clinical trials are under way to investigate whether antioxidants, such as vitamin E, or non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, could alleviate some of the toxic effects of β -amyloid (Kanaan et al., 1997; Blennow et al., 2006; St George-Hyslop, 2000).

Since phosphorylation/dephosphorylation mechanisms are crucial in the regulation of *Tau* and β -APP (Hwang et al., 2004; Iqbal and Grundke-Iqbal, 2006), a superfamily of mitogen-activated protein kinases (MAPKs) has recently emerged as key regulators of the formation of plaques, eventually leading to dementia and AD (Wang et al., 2004) (Fig. 1). To this end, this review will focus on the mechanisms mediated by MAPKs, which may modulate AD-related proteins and their functions and thereby can potentially determine the development of NFTs and, perhaps, the evolution of AD.

2. MAPK signaling modules and pathways: A network overview

2.1. MAPK signaling pathways as viewed through their identification and bifurcations

Signal transduction at the cellular level refers to the movement of signals (messages) from outside (extracellular) the cell to inside (intracellular) (Chattopadhyay and Brown, 2000; Dhanasekaran and Dermott, 1996; Guha and Mackman, 2001; Haddad, 2001; Haddad, 2002a; Haddad et al., 2002; Haddad et al., 2003; Holmes-McNary, 2002; Inui et al., 2001; Kim et al., 1999; Levin, 2002; Lowes et al., 2002; Meriin et al., 1998; Nakamura et al., 1996; 1998; 2002; Plyte et al., 2000; Sontag, 2001). The movement of signals can be simple, like that associated with receptor molecules of the acetylcholine class receptors that constitute channels which, upon ligand interaction, allow signals to be passed in the form of small ion movement, either into or out of the cell (Chattopadhyay and Brown, 2000; Dhanasekaran and Dermott, 1996; Guha and Mackman, 2001; Haddad, 2002b; Haddad et al., 2003; Pursiheimo et al., 2002; Sontag, 2001).

These ion movements result in changes in the electrical potential of the cells that, in turn, propagates the signal spatially along the cell. More complex

signal transduction, furthermore, involves the coupling of ligand-receptor interactions to many intracellular events. These events include phosphorylations by tyrosine kinases and/or serine/threonine kinases (Haddad, 2001; Haddad, 2002c; Haddad et al., 2003; Holmes-McNary, 2002; Levin, 2002; Lowes et al., 2002). The phosphorylation

of proteins may change enzyme activities and protein conformations. The eventual outcome is an alteration in cellular activity and changes in the programming of genes expressed within the responding cells (Haddad, 2005). Phosphorylation and dephosphorylation mechanisms schematically involved in the regulation of gene transcription are shown in Fig. 1.




Figure 1: A hypothetical model of gene regulation where the switch on/off mediates a series of phosphorylation/dephosphorylation steps regulated by kinases and phosphatases, respectively. This sequential propagation of signals occurs in response to a stimulus over a pre-specified period of time.

MAPKs were identified by virtue of their activation in response to growth factor stimulation of cells in culture, hence the name mitogen-activated protein kinases (Fig. 2) (Avruch et al., 2001; Cano and Mahadevan, 1995; Chakraborty, 2001; Haddad, 2002a; Haddad et al., 2003; Kennedy et al., 1999; Lee et al., 2000; Mordret, 1993; Pierce et al., 2001). MAP kinases are also called extracellular receptor kinases (ERKs) for extracellular-signal regulated kinases. On the basis of *in vitro* substrates, the MAP kinases have

been variously called microtubule associated protein-2 kinase (MAP-2 kinase), myelin basic protein kinase (MBP kinase), ribosomal S6 protein kinase (RSK-kinase; i.e., a kinase that phosphorylates a kinase) and epidermal growth factor (EGF) receptor threonine kinase (ERT kinase) (Avruch et al., 2001; Bardwell, 2006; Cano and Mahadevan, 1995; Chakraborty, 2001; Haddad, 2001; Haddad et al., 2003; Kennedy et al., 1999; Lee et al., 2000; Pierce et al., 2001). All of these proteins have similar biochemical properties,

immuno-cross-reactivities, amino acid sequence and ability to *in vitro* phosphorylate similar substrates.




Figure 2: The modules and various components of the MAPK signaling pathways. The cellular response to growth factors, inflammatory cytokines and other mitogens is often mediated by receptors that either are G-protein-linked or are intrinsic protein tyrosine kinases. The binding of the ligand to receptor tyrosine kinases induces dimerization and auto-phosphorylation (activation) of the kinase. The activated tyrosine kinase binds to and phosphorylates an adaptor protein, such as Grb2, that, in turn, activates a guanine nucleotide exchange factor, such as mSOS, that, in turn, activates a small GTP-binding protein, such as Ras or Rac. The GTP-binding proteins then transmit the signal to one of several cascades of protein Ser/Thr kinases that utilize the sequential phosphorylation of kinases to transmit and amplify the signal. These kinase cascades are collectively known as mitogen-activated protein kinase (MAPK) signaling cascades. The best studied of these kinase cascades is the MAPK^{ERK} (MAPK^{p44/p42}) signaling cascade. Downstream targets of MAPK^{ERK} include p90rsk (p90 ribosomal S6 protein kinase) and the Elk-1 and Stat3 transcription factors. The Jun kinase (MAPK^{JNK/SAPK}) and MAPK^{p38} kinase (HOG) pathways are stress-activated MAP kinase cascades. The MAPK^{JNK} cascade is activated by inflammatory cytokines as well as by heat shock and UV irradiation. Downstream targets of MAPK^{JNK} include the transcription factors c-Jun and ATF-2. The MAPK^{p38} pathway is activated by bacterial endotoxins, inflammatory cytokines and osmotic stress. Downstream targets of MAPK^{p38} include the transcription factors ATF-2, Max and CREB. MAPK^{p38} is also involved in the phosphorylation and activation of heat shock proteins.

Maximal MAP kinase activity requires that both tyrosine and threonine residues are phosphorylated. This indicates that MAP kinases act as switch kinase that transmits information of increased intracellular

tyrosine phosphorylation to that of serine/threonine phosphorylation (Guan, 1994; Haddad 2001; Haddad 2002d; Ono and Han, 2000; Sugden and Clerk, 1997). Although MAP kinase activation was first observed in

response to activation of EGF, platelet-derived growth factor (PDGF), nerve growth factor (NGF) and insulin and insulin-like receptors, other cellular stimuli such as T-cell activation (which signals through the Lck tyrosine kinase), phorbol esters (that function through activation of protein kinase C (PKC)), thrombin, bombesin and bradykinin (that function through G-proteins), as well as *N*-methyl-D-aspartate (NMDA) receptor activation and electrical stimulation rapidly induce tyrosine phosphorylation of MAP kinases (Avruch et al., 2001; Cano and Mahadevan, 1995; Chakraborty, 2001; Guan, 1994; Kennedy et al., 1999; Lee et al., 2000; Mordret, 1993; Ono and Han, 2000; Pierce et al., 2001; Sugden and Clerk, 1997).

MAP kinases are, however, not the direct substrates for receptor tyrosine kinases (RTKs) or receptor-associated tyrosine kinases but are in fact activated by an additional class of kinases termed MAP kinase kinases (MAPK kinases) and MAPK kinase kinases (MAPKK kinases). One of the MAPK kinases has been identified as the proto-oncogenic serine/threonine kinase, Raf (Bendinelli et al., 1995; Cazaubon et al., 1994; Chen et al., 1996; Cobb et al., 1994; English and Cobb, 2002; Errede et al., 1995; Haddad 2001; Hagemann and Blank, 2001; Kolch, 2000; Lee and McCubrey, 2002; Liebmann, 2001; Marshall, 1995; McCubrey et al., 2000; Morrison, 1995; Oppenheimer et al., 2000; Schlesinger et al., 1998; Sebolt-Leopold, 2000; Tibbles and Woodgett, 1999; Weinstein- Zhu et al., 2001b).

Ultimate targets of the MAP kinases are several transcriptional regulators such as serum response factor (SRF) and the proto-oncogenes Fos, Myc and Jun, as well as members of the steroid/thyroid hormone receptor super family of proteins. The simplified core of a MAPK cascade consists of three protein kinases: A MAP kinase kinase kinase (MAPKKK), a MAP kinase kinase (MAPKK) and MAP kinase (MAPK); these kinases phosphorylate each other in sequence. When activated, MAPKKK phosphorylates the MAPKK at one or two phosphorylation sites, bringing activation of the MAPKK module. MAPKKs are dual-specificity protein kinases that phosphorylate the MAPK at two phosphorylation sites (almost always a threonine and a tyrosine residue), bringing about activation of the MAPK. The active MAPK can then phosphorylate a variety of target proteins throughout the cytoplasm and nucleus (Bardwell, 2006).

On the internal regulatory mechanisms, each of the kinases in the MAPK cascade is opposed by one or more phospho-protein phosphatases. Thus, for an active MAPKK to activate a MAPK, for example, the rate of MAPK phosphorylation must exceed the rate of MAPK de-phosphorylation. The activities of these phosphatases are high enough to make the output of a MAPK cascade depend upon the continual presence of a stimulus feeding into the cascade; if this particular stimulus is withdrawn, for instance, the downstream kinases become inactivated within a very short lapse of time (Figure 2) (Avruch et al., 2001; Cano and Mahadevan, 1995; Chakraborty, 2001; Cullen and Lockyer, 2002; English and Cobb, 2002; Haddad et al., 2003; Kennedy et al., 1999; Lee and McCubrey, 2002; Lee et al., 2000; Mordret, 1993; Pierce et al., 2001).

The best-characterized vertebrate MAPKs fall into three major subgroups (Figure 2). The first subgroup includes the founding members of the MAPK family, extracellular signal-regulated kinase-1 (ERK1; MAPK^{ERK1/p44}) and ERK2 (MAPK^{ERK2/p42}), and their closest relatives (Bardwell, 2006; Belcheva and Coscia, 2002; Daulhac et al., 1997; Denhardt, 1996; Frye, 1992; Howe et al., 2002; Peyssonnaud and Eychene, 2001; Zhang et al., 2000). This subgroup is often referred to as ERKs, although some ERK proteins are not in fact members of this subgroup family.

The second subgroup is the Jun N-terminal kinases (JNKs), so called because they can activate the Jun transcription factor by phosphorylating two residues near its N-terminus (Barr and Bogoyevitch, 2001; Davis, 2000; Dickens et al., 1997; Dong et al., 2001; Fleming et al., 2000; Harper and LoGrasso, 2001; Ip and Davis, 1998; Leppa and Bohmann, 1999; Mielke and Herdegen, 2000; Noselli, 1998; Noselli and Agnes, 1999; Okazawa and Estus, 2002; Rincon et al., 2000; Weston and Davis, 2002; Yao et al., 1997).

The third subgroup is the p38 MAPKs, so named because of the molecular weight (38 kDa) of the first representative of the subgroup to be discovered (Bulavin et al., 2002; English et al., 1999; Haddad, 2001; Ichijo, 1999; Lee and Young, 1996; Lopez-Illasaca, 1998; Obata et al., 2000; Rincon, 2001). Members of both the MAPK^{JNK} and MAPK^{p38} pathways are also classified as stress-activated protein kinases (SAPKs), because they are activated in

response to osmotic shock, UV irradiation, inflammatory cytokines and other stressful conditions (Haddad et al., 2003).

In all three subgroups, a large number of MAPKKs feed into the activation of a smaller number of MAPKKs and MAPKs. The diversity of the

MAPKKs thus allows a wide variety of upstream receptors to couple to MAPK cascades (Fig. 2) (Haddad, 2002a; Haddad, 2002f; Haddad and Land, 2002; Lewis et al., 1998; Marshall, 1994; Pearson et al., 2001). MAPKs and their corresponding substrates are given in Table 1.

Table 1: MAPKs and downstream transcription factors and substrates.

KINASE	SUBSTRATES
MAPK ^{ERK}	Elk-1; SAP-1; Mnk-1/2; MAPKAP-K1/p90 ^{Rsk} ; MSK-1
MAPK ^{JNK/SAPK}	c-Jun; ATF-2; Elk-1
MAPK ^{p38}	ATF-2; Elk-1; SAP-1; CHOP; MEF2C; MAPKAP-K2/K3; Mnk-1/2; MSK-1; PRAK
MAPKAP-K1/p90 ^{Rsk}	c-Fos; SRF
MSK-1	CREB; Histone H3 and HMG-14

ATF, Activating transcription factor; CHOP, C/EBP homologous protein; CREB, cAMP response element binding protein; HMG-14, High mobility group-14; MAPK^{ERK}, mitogen-activated protein kinase/extracellular signal-regulated kinase; MAPKAP-K, MAPK-activated protein kinase; MEF2C, Myocyte enhancer factor 2C; Mnk, MAPK interacting protein kinase; MSK, Mitogen- and stress-activated protein kinase; PRAK, p38-related/activated protein kinase; Rsk, Ribosomal S6 kinase; SAP-1, SRE accessory protein-1; SRF, Serum response factor.

2.2. MAPK signaling as viewed through receptor and non-receptor coupled cofactors

The MAPKs are a grouping of closely related families of Ser/Thr kinases involved in regulating growth, differentiation, and cellular responses to stress or inflammatory cytokines (Haddad and Fahlman, 2002; Haddad et al., 2003). Whereas the MAPK^{ERK} pathway essentially regulates growth, proliferation and differentiation signals, the MAPK^{JNK/SAPK} and MAPK^{p38} pathways regulate cell responses to environmental stress.

The MAPKs link signals generated at the cell surface to transcription factors via a cascade of phosphorylation events basically initiated at the level of the membrane by protein tyrosine kinases (PTKs), of which two classes exist, the receptor PTKs and non-receptor PTKs. Among the PTKs is the Src family of non-receptor PTKs composed of at least

nine members. Most are restricted to defined cellular lines, but three (Src, Fyn, Yes) are ubiquitously expressed (Courtneidge et al., 1993; Haddad, 2002d; Haddad et al., 2003). Like their receptor PTK counterparts, the Srcs are at the upper end of the MAPK cascade and serve as initiators for the transduction of signals generated by receptors at the cell surface (Akhand et al., 2002; Pawson, 1994; Parsons and Parsons, 1997).

The Ras G-proteins mediate the mitogen-induced activation of MAP kinases by activating Raf, a family of serine/threonine kinases (Hindley and Kolch, 2002). The MEK1 and MEK2 are the dominant Raf effector proteins, although other Raf substrates have been identified (Pearson et al., 2000). Deactivation of the MAP kinases is an important regulatory feature of the cascade. This is accomplished by phosphatases such as MKP-1/2 PAC-1 that dephosphorylate

MAPK^{ERK} in the nucleus or MPK-3, which dephosphorylate cytosolic MAPK^{ERK} (Haneda et al., 1999). The MAP kinases therefore are a convergence point for a wide variety of extracellular signals. MAPK circuits are a three tiered module consisting of Raf → MEK → MAPK^{ERK} conveying signals from receptor TKs and G-protein coupled receptors to transcription factor in the cell nucleus (Erickson et al., 1990; Haddad et al., 2003; Ravichandran, 2001; Ray and Sturgill, 1987; Tian and Feig, 2001).

Two other signaling cascades are part of the MAP kinase system. The stress-induced MAPK^{p38} mediates inflammatory or stress responses to cytokines, such as tumor necrosis factor (TNF), genotoxic agents, osmotic shock, bacterial lipopolysaccharides, photo-damage from ultraviolet light, as well as from growth factor withdrawal. The other pathway, MAPK^{JNK/SAPK}, transduces several stress signals including oxidation/DNA damage along with growth and differentiation signals. Both of these pathways are activated by a Rac-1 and Cdc-42 signals, which can also activate the MAPK^{ERK1/2} system (Vacratsis and Gallo, 2000) (Fig. 3).





Figure 3: An overview of the complex network of MAPK signaling pathways and their interactions and bifurcations. The sign  denotes inhibition, the solid arrows indicate activation (stimulation); P, phosphorylation.

The three MAPK pathways do not act in isolation but in parallel with limited cross-talk possible. MEKK-3 directly activates both MKK-6 (activator of MAPK^{p38}) and MKK-7 (activator of MAPK^{JNK}), while MKK-4 (activator of MAPK^{JNK} and MAPK^{p38}) is activated by

MEKK-2 and MEKK-3. The MAPK^{JNK} pathway activates the tumor suppressor gene, p53, which has recently been demonstrated to counteract Cdc-42 (Kumar et al., 1997; Enslin et al., 1998; Herlaar and Brown, 1999; Cuenda, 2000; Mielke and Herdegen,

2000; Gadea et al., 2002; Hazzalin and Mahadevan, 2002; Haddad et al., 2003) (Figure 3). (For further details on MAPKs signaling pathways, refer to Haddad et al., 2003.)

3. Alzheimer's disease: An overwhelming etiological condition or a maneuverable syndrome?

AD is the most common cause of dementia in older people (Li et al., 2001; Marx, 2001). Simply put, it's a medical condition that disrupts the way the brain works. AD most notably affects the parts of the brain that control thought, memory and language (Martindale, 2002). Although the risk of getting the disease increases with age, it is not a normal part of aging (St George-Hyslop, 2000). AD is characterized by adult-onset slowly progressive dementia associated with diffuse cerebral atrophy on neuro-imaging studies. AD is named after Dr. Alois Alzheimer, a German psychiatrist (Bardwell, 2006; Wurtman, 1985).

In 1906, Dr. Alzheimer described changes in the brain tissue of a woman who had died of an unusual mental illness. He found abnormal deposits (called senile or neuritic plaques) and tangled bundles of nerve fibers (called NFTs). These plaques and tangles in the brain have come to be characteristic brain changes due to AD. The diagnosis of AD is based on the histological findings of β -amyloid plaques and intra-neuronal neurofibrillary tangles. A significant association with the e4 allele of apo-lipoprotein E supports the diagnosis of AD in patients with dementia and increases the risk that asymptomatic individuals will eventually develop AD. *ApoE* genotyping, however, is neither fully specific nor sensitive (Bardwell, 2006).

Early and careful evaluation is important because many conditions can cause dementia, some of which are treatable or 'reversible.' Potentially reversible conditions include depression, adverse drug reactions, metabolic changes, and nutritional deficiencies (St George-Hyslop, 2000). A comprehensive patient evaluation includes a complete health history, physical examination, neurological and mental status assessments, and other tests including analysis of blood and urine, electrocardiogram, and an imaging exam, such as CT or MRI (Anderson et al., 2005). While this type of evaluation may provide a diagnosis of possible or probable AD, confirmation requires examination of brain tissue at autopsy.

Although no cure for AD is yet available, medical and social management of the disease can ease the burdens on the patient, and his or her caregiver and family (St George-Hyslop, 2000). To date there are four FDA-approved drugs for the treatment of AD — tacrine (Cognex®), donepezil (Aricept®), rivastigmine (Exelon®) and galantamine (Reminyl®) — and several others in clinical trials. In addition to treating the symptoms, advising the patient and his or her caregiver to initiate health care directives and decisions while the patient still has the capacity to do so can ease the burden for the family as the disease progresses (Beardsley, 1995; St George-Hyslop, 2000; Martindale, 2002).

4. The role of MAPKs in Alzheimer's: Mechanisms and possible therapeutic targets

4.1. Paired helical filaments and Tau phosphorylation

Paired helical filaments (PHFs) are a characteristic pathological feature of AD; their principal component is the microtubule-associated protein *Tau* (Fig. 4). The *Tau* in PHFs (PHF-*Tau*) in AD is hyper-phosphorylated, but the cellular mechanisms responsible for this hyper-phosphorylation are still being elucidated (Ganju et al., 1998; St George-Hyslop, 2000; Zhao et al., 2003). MAPKs are a family of Ser/Thr kinases that link cell surface signals to changes in enzyme activity and gene expression (Shanavas and Papasozomenos, 2000; Haddad, 2002d; Haddad et al., 2003).

Moreover, MAPKs have been shown to phosphorylate *Tau in vitro* at Ser/Thr proline sites, thereby generating a multiply phosphorylated *Tau* protein that is similar to the hyper-phosphorylated *Tau* found in AD neurofibrillary tangles (NFT) (Dalrymple, 2002; Johnson and Bailey, 2003; St George-Hyslop, 2000). For instance, fluorescence resonance energy transfer (FRET) studies demonstrated a tight intermolecular association of activated MAPK with these phospho-*Tau* epitopes (Knowles et al., 1999). The phosphorylation of normal *Tau* by MAPKs such as MAPK^{ERK} induced *Tau* to acquire biochemical properties of AD PHF proteins. In this regards, it was shown that a monoclonal antibody to MAP kinases could recognize MAPK^{ERK2} (MAPK^{p42}) in normal and AD cortex, but MAPK^{ERK2} levels were slightly reduced in the AD brain (Trojanowski et al., 1993). The hypothesis was that since MAPK^{ERK2} was

detected in NFTs and senile plaque neurites in the AD hippocampus, MAPK^{ERK2} was positioned to

phosphorylate normal *Tau* and could possibly play a role in the generation of PHFs in AD.




Figure 4: Schematic diagram depicting the role of kinases and phosphatases acting on *Tau* protein in AD. *Tau* contains specific phosphorylation sites that are apparently critical for hyper-phosphorylation in AD. One class comprises the Ser-Pro and Thr-Pro motifs that determine the reactivity with diagnostic antibodies; the other class contains, at least, Ser-262 and has a strong effect on microtubule binding. Proline-directed kinases such as MAPKs, GSK-3 and Cdk-5 basically phosphorylate Ser-Pro or Thr-Pro motifs, and the Serine-specific kinase phosphorylates Ser-262 in the first repeat and the corresponding serines in the other repeats. AD-derived brain extracts usually contain a mixture of the aforementioned kinases. The phosphatases calcineurin and PP-2A can remove the phosphates from *Tau* as well as from AD PHFs, thereby acting in an endogenous negative feedback mechanism.

In contrast, activating MAPK in cultures of primary neurons or transfected COS cells expressing *Tau* isoforms did not increase the level of phosphorylation for any PHF-*Tau* epitope investigated (Lovestone et al., 1994). However, elevating glycogen synthase kinase (GSK)-3 activity in the COS cells by co-transfection with GSK-3 α or GSK-3 β decreased the electrophoretic mobility of *Tau* so that it resembled that of PHF-*Tau*, and induced reactivity with PHF-

Tau-selective monoclonal antibodies (Aplin et al., 1996; Lovestone et al., 1994).

These observations were reinforced by the construction of mammalian cell culture systems producing high levels of intracellular phosphorylated *Tau*. COS-1 fibroblast-like cells were transiently transfected to simultaneously express *Tau*, MAPK and MAPKK, or alternatively to express *Tau* and GSK-3

(Aplin et al., 1996; Baum et al., 1995). B103 neuron-like cells (which contain MAPK but little *Tau* or GSK-3) were stably transfected to express *Tau* or *Tau* and GSK-3. In both systems, GSK-3 transfected cells contained *Tau* AT-8/M (defined by AT-8 staining and *Tau* PHF-like mobility), but MAPK-transfected cells required phosphatase inhibitors, such as okadaic acid (OKA) or calyculin (CAL), to produce *Tau* AT-8/M. *In vitro*, CAL and OKA inhibited protein phosphatase (PP)-1 and PP-2A.

In addition, inducing *Tau* phosphorylation at the AT-8 site in MAPK-transfected cells required 2-10 times more OKA than CAL, suggesting both PP-1 and PP-2A helped block the phosphorylation (Baum et al., 1995; Tanaka et al., 1998). Though levels of *Tau* AT-8/M increased in COS-1 cells, the ratio of particulate to supernatant *Tau* levels did not change, and no tangles were observed; it was suggested that post-translational modifications or co-aggregating proteins were likely needed to induce PHF (Ghribi et al., 2003).

4.2. *Tau* phosphorylation and MAPK inhibition

Mobility shift, phospho-epitope analysis and direct measurement of kinase activity indicated that the MEK-1 inhibitor (PD-098059) dose-dependently blocked basal and OKA-induced MAPK activation (Ekinici and Shea, 1999; Ho et al., 1997; Rapoport and Ferreira, 1999, 2000; Schneider et al., 1999). Despite a block of MAPK activation by this inhibitor, robust *Tau* hyper-phosphorylation was observed in response to OKA. In addition, activation of MAPK by phorbol 12-myristate 13-acetate (PMA) did not result in *Tau* phosphorylation, indicating that in primary cultures of cortical neurons elevated MAPK activity was not sufficient to induce *Tau* hyper-phosphorylation.

Similarly, using immuno-histochemistry, Yamaguchi et al. (1996) examined the localization of four types of proline-directed kinases in the brains of control rats and in the brains of non-demented aged human subjects, subjects with AD and those with Down's syndrome. The four kinases were: cyclin-dependent kinase (cdk)-5, a component of *Tau* protein kinase (TPK)-II, TPK-I/GSK-3 β , GSK-3 α and MAPK^{ERK2}. Antiserum for cdk-5 showed the most preferential and consistent labeling of intra-neuronal NFT. Antiserum for TPK I/GSK-3 β also labeled intra-neuronal NFT. Double immuno-labeling for TPK I/GSK-3 β and *Tau*-

1 showed that TPK I/GSK-3 β was closely associated with NFT.

Antiserum for GSK-3 α labeled neurons weakly and the intensity of labeling did not differ between neurons with and without NFT. In addition, antiserum for MAPK labeled neurons in superficial cortical layers, but NFT appeared in both superficial and deep cortical layers (Reynolds et al., 2000; Yamaguchi et al., 1996). These findings suggested that cdk-5 and TPK I/GSK-3 β are the critically important kinases for the generation *in vivo* of hyper-phosphorylated *Tau*, the main component of the paired helical filaments in NFT.

In concert with these observations, the novel brain protein kinase PK-40 was characterized by its ability to phosphorylate Lys-Ser-Pro sites in neuro-filament and *Tau* proteins (Mandelkow et al., 1993). PK-40 is recognized as a member of the family of MAPK^{ERK} by its reactivity with MAPK^{ERK}-specific antibodies (PK-40^{ERK}). Particularly, protein sequence analysis suggested that PK-40 is a form of MAPK^{ERK2}. Bovine *Tau* or recombinant human *Tau* proteins can be hyper-phosphorylated by PK-40^{ERK} to produce the electrophoretic mobility shifts and certain immunochemical properties characteristic of PHF-*Tau* isolated from AD brain tissue (Trojanowski et al., 1993).

On the mechanisms related to PK-40^{ERK}, a cAMP-dependent protein kinase A (PKA)-mediated pathway is involved. It was observed that PKA phosphorylates *Tau* to a lesser extent; however, the product is not like the hyper-phosphorylated *Tau* of AD in several important respects. Subsequently, it was reported that *in vitro* PK-40^{ERK} further phosphorylates *Tau* that was previously saturated by PKA, provided that the concentrations of free un-complexed ATP are low (Blanchard et al., 1994; Raghunandan and Ingram, 1995). Interestingly, the actions of different kinases on *Tau* are not independent, but may depend on the order in which they work on *Tau*; i.e., prior phosphorylation by PKA partially inhibits the action of PK-40^{ERK}.

Furthermore, a subpopulation of MAPK^{ERK2} species in soluble brain fractions can be efficiently phosphorylated and activated in cell-free systems, simply by adding Mg²⁺-ATP. Two phospho-isoforms of PK-40^{ERK2} are formed in this process, which have

reduced gel mobility, very much like the MAPK^{ERK2} form obtained in cell culture by stimulation with growth factors (Roder et al., 1993; Roder et al., 1995). One of these low-mobility forms cannot be inactivated with PP-2A or with tyrosine phosphatases; the second form can be slowly inactivated by PP-2A. In this case two Ser/Thr phosphates are removed at different rates during inactivation: One phosphate is very quickly removed to result in the formation of a high-mobility 39-kDa MAPK^{ERK2} species without consequence for activity; the other, slowly removed Ser/Thr phosphate controls the activity but has no effect on the gel mobility of MAPK^{ERK2}. These results unequivocally showed that forms of MAPK^{ERK2} exist with properties different from the previously characterized MAPK^{ERK2} (MAPK^{p42}) from stimulated cell cultures. The active MAPK^{ERK2} forms produced in the presence of Mg²⁺-ATP alone could provide an explanation for the existence of constitutive MAPK^{ERK2}-like NFT phosphorylation *in vivo*. Excessive formation of an MAPK^{ERK2} species resistant to inactivation by PP-2A might be relevant to the persistent pathological *Tau* hyper-phosphorylation in AD. It was subsequently postulated that PK-40^{ERK} might play a crucial role in the etiology of this disease (Roder et al., 1993; Roder et al., 1995).

Furthermore, incubation of rat, human and rhesus monkey temporal neo-cortex slices with the phosphatase inhibitor OKA induced epitopes of *Tau* similar to those found in PHFs. OKA induced variant forms of *Tau* at 60-68 kDa, which were recognized by the monoclonal antibodies Alz-50 (in humans only) and 5E2 and two polyclonal anti-peptide antisera, OK-1 and OK-2 (Garver et al., 1995). The phosphorylation-sensitive monoclonal antibody *Tau*-1 failed to recognize the slowest mobility forms of *Tau* after okadaic acid treatment. Moreover, FK-520 (1-10 μ M), a potent inhibitor of calcineurin activity, was tested in brain slices and found not to alter *Tau* mobility. However, combinations of FK-520 and OKA caused *Tau* mobility shifts similar to those seen after OKA treatment; similar results were seen using the calcineurin-selective inhibitor cyclosporin (Garver et al., 1995). Treatment of human slices with OKA decreased both PP-2A and calcineurin activity; FK-520 inhibited only PP-2B activity. A proposed *Tau*-directed kinase, 42-kDa MAPK^{ERK2}, was activated by OKA but not FK-520. Of note, NGF activated MAPK^{ERK2}, particularly when used in combination with OKA; changes in *Tau* mobility were

seen when this kinase was activated. Forskolin, in addition, antagonized the effects of NGF on both MAPK^{ERK2} activity and *Tau* phosphorylation and forskolin alone had little effect on PHF-like *Tau* formation induced by phosphatase inhibitors, outlining complex interactions between *Tau*-directed protein kinases and protein phosphatases and suggesting potential sites for therapeutic targeting.

4.3. *Tau* structural analysis and MAPK-related protein phosphorylation

The interactions of *Tau* protein with microtubules could be visualized from two points of view, phosphorylation and domain structure (Anderton et al., 2001; Angulo et al., 2003; Floyd, 1999; James et al., 1996; Jenkins et al., 2000; Mandelkow et al., 1995; Stein and Johnson, 2003). *Tau* can be phosphorylated at many sites and by several kinases, notably by proline-directed kinases (MAPK, GSK-3, cdk-5), which generate Alzheimer-like antibody epitopes. Other kinases phosphorylate Ser 262, a site that has a particularly pronounced influence on the affinity of *Tau* for microtubules (Fig. 4). All of these sites can be cleared by phosphatases PP-2A and CAL. The site Ser-262 lies within the repeat domain of *Tau*. However, when probing the domains of *Tau* for their effects on microtubule binding, nucleation, assembly, or bundling, the repeat domain has only a weak influence. Whereas the repeat domain of *Tau* binds to microtubules with low affinity, repeat-less *Tau* binds strongly yet unproductively in terms of microtubule assembly.

Productive binding of *Tau* to microtubules depends on the combination of repeats with the flanking regions, as if the flanking regions acted as 'jaws' for the proper positioning of *Tau* on the microtubule surface. Analysis of phosphorylation of *Tau* is often performed using phosphorylation-sensitive monoclonal antibodies thought to report the presence or absence of one or two specific phosphorylations (cognate sites). Using several such antibodies, it was found that a much more complicated relationship existed between phosphorylation at specific sites, as monitored by two-dimensional phospho-peptide mapping, and antibody recognition of these sites (Roder et al., 1997). Multiple phosphorylation of *Tau* in several stages by PK-40, for instance, suggested that phosphorylation at cognate sites is sometimes necessary, but not sufficient, to induce a change of antibody reactivity and in some cases is not even necessary in the

background of multiple phosphorylation at other sites. No single phosphorylation site was found to be responsible for any level of gel mobility shift associated with phosphorylation. Moreover, *Tau* acquired its maximal gel mobility retardation and final immunochemical profile at sub-stoichiometric phosphorylation of most sites. This suggested that many alternate phosphorylation patterns could produce the same conformational and immunochemical presentation on SDS-PAGE. Although PK-40^{ERK2} prefers some phosphorylation sites, most notably Ser-235, followed by Ser-199 or Ser-202 and Thr-205, the phosphorylation of multiple Ser/Thr-Pro sites is not highly sequential (Fig. 4). Ser-396 is one of the least preferred sites and seems to require prior phosphorylation at Ser-404.

Moreover, MAPK immunoreactivity and *in situ* hybridization patterns of the two major genes that comprise MAPK activity, MAPK^{ERK1} and MAPK^{ERK2}, were reported in the human hippocampal formation (Hyman et al., 1994). The goal was to determine whether the pattern of MAPK^{ERK} expression was consistent with the hypothesis that MAPKs directly contribute to NFT formation. MAPK^{ERK1} mRNA was detected in small amounts and confined primarily to dentate gyrus granule cells (Hyman et al., 1994). MAPK^{ERK2} mRNA, by contrast, gave a much stronger hybridization signal and was present in dentate gyrus granule cells and pyramidal cells throughout all hippocampal sub-fields and adjacent temporal neocortex. Quantitative measures of MAPK^{ERK2} mRNA revealed that neuro-filament bearing neurons contained approximately 15% less MAPK^{ERK2} mRNA than nearest normal neighbors (Hyman et al., 1994). NFT-bearing neurons contained approximately 25% less poly-A mRNA, suggesting a relative preservation of MAPK^{ERK2} mRNA even in metabolically compromised cells.

MAPK immunoreactivity (which represented both MAPK^{ERK1} and MAPK^{ERK2}) was reported in neuronal soma, dendrites, axons and in reactive astrocytes (Hyman et al., 1994). In AD, neurons that contain NFTs are also MAPK immunoreactive, but neurons that contain the highest amounts of MAPK immunoreactivity are not necessarily vulnerable for NFTs. MAPK immunoreactivity was present in the same neurons as NFTs and in the same subcellular compartments as *Tau*, supporting a role for MAPKs in *Tau* phosphorylation in AD. However, the presence of

MAPK^{ERK} immunoreactivity was not sufficient to predispose neurons to NFT formation (Korneyev, 1998).

4.4. *Tau/β-APP-mediated phosphorylation mechanisms and MAPK regulation*

Biological effects related to cell growth, as well as a role in the pathogenesis of AD, have been ascribed to the β-amyloid precursor protein (β-APP). The aberrant expression or processing of β-APP is the only known genetic basis for presenile familial AD, and the molecular connection between β-APP and *Tau* has always been perplexing (Grant et al., 1999; Jones et al., 1999; Wirths et al., 2006). Transgenic experiments, for instance, have revealed that long-term memory is dependent on cAMP-response element binding protein, CREB (Sato et al., 1997). CREB phosphorylation at Ser-133 is essential for its transcriptional activity. In this respect, it was demonstrated that β-APP induced CREB phosphorylation at Ser-133 in rat pheochromocytoma PC-12 cells. β-APP, furthermore, induced the phosphorylation of MAPK^{ERK1} and MAPK^{ERK2} at Tyr-204, and PD-98059, a MEK1 inhibitor, inhibited β-APP-induced CREB phosphorylation at serine-133 (Sato et al., 1997). It was concluded that elevated β-APP level induces CREB phosphorylation at Ser-133 via MAPK^{ERK1/2}-dependent pathway.

In addition, it was reported that the secreted form of β-APP potently stimulates MAPKs. For instance, brief exposure of PC-12 pheochromocytoma cells to β-APP secreted by transfected Chinese hamster ovary cells stimulated the 43-kDa form of MAPK (Greenberg et al., 1994). Induction of a dominant inhibitory form of Ras in a PC-12-derived cell line prevented the stimulation of MAPK by secreted β-APP, demonstrating the dependence of the effect upon p21-Ras. Moreover, it was found that enhancement in *Tau* phosphorylation was associated with the β-APP-induced MAPK stimulation (Greenberg et al., 1994). In the Ras dominant inhibitory cell line, β-APP failed to enhance phosphorylation of *Tau*, thereby providing a link between secreted β-APP and the phosphorylation state of *Tau*. Furthermore, β-APP has been shown to serve as a G₀-coupled receptor in cell-free systems (Okamoto et al., 1995). It was shown that stimulation of β-APP by anti-APP antibody as well as by a mutation found in familial AD resulted in the activation of a specific set of MAPK in multiple

vertebrate cells (Murayama et al., 1996), thereby concluding that β -APP might act as a cell surface receptor of biological relevance that turns on specific Ser/Thr kinases, and suggested that the signaling function of β -APP is a potential target of familial AD mutations (Oakley et al., 2006).

On the mechanisms reported, β -APP, which accumulates extracellularly in AD brain, induces Ca^{2+} influx in culture via the L -gated voltage-sensitive Ca^{2+} channel. Since this channel is normally activated by PKA-mediated phosphorylation, kinase activities recruited following β -APP treatment of cortical neurons and SH-SY-5Y neuroblastoma were examined. β -APP increased channel phosphorylation; this increase was unaffected by the PKA inhibitor, H89, but was reduced by PD-98059 (Abe and Saito, 2000; Ekinici et al., 1999; Guise et al., 2001).

Pharmacological and antisense oligonucleotide-mediated reduction of MAPK activity also reduced β -APP-induced accumulation of Ca^{2+} , reactive oxygen species (ROS), phospho-*Tau* immunoreactivity and apoptosis, indicating that MAPK mediates multiple aspects of β -APP-induced neuro-toxicity and suggesting that Ca^{2+} influx initiates neuro-degeneration in AD (Zhang and Jope, 1999). In addition, β -APP increased MAPK-mediated phosphorylation of membrane-associated proteins and reduced phosphorylation of cytosolic proteins without increasing overall MAPK activity (Ekinici et al., 1999). Increasing MAPK activity with EGF did not increase channel phosphorylation, to indicate that redirection, rather than increased activation, of MAPK activity mediates β -APP-induced neuro-toxicity (Canet-Aviles et al., 2002).

Another mechanism known involves phosphatidylinositol 3-kinase (PI3-K) (Shaw et al., 2001). Because of the physiological role of PI3-K in the translocation of glucose transporter-containing vesicles, it was speculated that PI3-K involvement in β -APP metabolism might act at the level of vesicular trafficking (Solano et al., 2000). In accord with the aforementioned observations, exposure of primary rat microglia and human THP-1 monocytes to β -APP resulted in the tyrosine kinase-dependent activation of two parallel signal transduction cascades involving members of the MAPK superfamily. β -APP stimulated the rapid, transient activation of

MAPK^{ERK1/2} in microglia and only MAPK^{ERK2} in THP-1 monocytes (McDonald et al., 1998).

A second superfamily member, MAPK^{p38}, was also activated with similar kinetics. Scavenger receptor and receptor for advanced glycated end products (RAGE) ligands failed to activate MAPK^{ERK} and MAPK^{p38} in the absence of significant increases in protein tyrosine phosphorylation, demonstrating that scavenger receptors and RAGE are not linked to these pathways (McDonald et al., 1998; Sun et al., 2003). Importantly, MAPK^{JNK} SAPKs were not significantly activated in response to β -APP. Moreover, exposure of microglia and THP-1 monocytes to β -APP resulted in the activation of RSK-1 and RSK-2 and phosphorylation of CREB at Ser-133, providing a mechanism for β -APP -induced changes in gene expression (McDonald et al., 1998).

In reinforcement of these reports, Shin et al. (1999) investigated the role of presenilin-1 (PS-1) in the secretion of α -secretase derived sAPP- α and associated intracellular signaling pathways. Human embryonic kidney (HEK) 293 cells, in this respect, were transfected with exon-9 deletion (Δ E9) mutant PS-1 cDNA in an ecdyson-inducible system. sAPP- α secretion was lower in the mutant PS-1 expressing cells compared with non-expressing cells (Shin et al., 1999). When activated by PDBu, secretion of sAPP- α and the level of phosphorylated MAPK were enhanced in Δ E9 PS-1 un-induced cells, but not in the mutant PS-1 induced cells. PD-98059, in addition, blocked PDBu induced sAPP- α secretion from Δ E9 PS-1 un-induced cells, but had no effect on the mutant PS-1 induced cells, indicating that PS-1 mediates PDBu-induced sAPP- α secretion and MAPK activation.

In contrast to the neutral role of MAPK^{JNK} and MAPK^{p38} in AD, using nano-electrospray mass spectrometry, an extensive phosphorylation *in vitro* by several candidate *Tau* kinases, namely, MAPK^{JNK}, MAPK^{p38}, MAPK^{ERK2} and GSK-3 β was observed (between 10 and 15 sites were identified for each kinase). The three MAPKs phosphorylated Ser-202 and Thr-205 but not detectably Ser-199, whereas conversely GSK-3 β phosphorylated Ser-199 but not detectably Ser-202 or Thr-205 (Otth et al., 2003; Reynolds et al., 2000; Troy et al., 2001). In addition, phosphorylated Ser-404 was found with all of these

kinases except MAPK^{JNK}. To recapitulate, the MAP kinases may not be strictly proline specific: MAPK^{p38} phosphorylated the non-proline sites Ser-185, Thr-245, Ser-305 and Ser-356, whereas MAPK^{ERK2} was the strictest. Furthermore, all of the sites detected except Thr-245 and Ser-305 are known or suspected phosphorylation sites in paired helical filament-*Tau* extracted from AD brains, suggesting that the three MAPKs are importantly all strong candidates as *Tau* kinases that may be involved in the pathogenic hyperphosphorylation of *Tau* in AD (Reynolds et al., 2000; Zhu et al., 2000).

In addition, Thr-668 within the carboxy-terminus of the AD β -APP is a known *in vivo* phosphorylation site. Phosphorylation of β -APP/Thr-668 is believed to regulate β -APP function and metabolism (Standen et al., 2001). Thr-668 precedes a proline, which suggests that it is targeted for phosphorylation by proline-directed kinase(s). The ability of four major neuronally active proline-directed kinases, cdk-5, GSK-3 β , MAPK^{ERK2} and MAPK^{JNK1} to phosphorylate β -APP/Thr-668 indicated a robust phosphorylation of this site both *in vitro* and *in vivo* (Figure 4) (Matsuda et al., 2001; Troy et al., 2001).

Another interesting mechanism reported for the action of β -APP in AD indicated a major role for glutamate, the principal excitatory neurotransmitter in the mammalian brain. Several lines of evidence suggested that glutamatergic hypo-activity exists in the AD brain, where it may contribute to both brain amyloid burden and cognitive dysfunction (Mills and Reiner, 1999). Although metabotropic glutamate receptors (Haddad, 2005) have been shown to alter cleavage of β -APP, little attention has been paid to the role of NMDA receptors in this process. It was reported that the activation of NMDA receptors in transiently transfected human embryonic kidney 293 cells increased the production of sAPP (Mills and Reiner, 1999).

Moreover, using both pharmacological and gene transfer techniques, it was shown that this effect was largely due to activation of the MAPK, specifically MAPK^{ERK}. These observations further our understanding of the pathways that regulate APP cleavage and buttress the notion that regulation of β -

APP is critically dependent upon MAPKs (Bi et al., 2000).

Conversely, β -APP has been reported to induce the phosphorylation of MAPKs. For instance, using acute and organotypic hippocampal slice preparations, Dineley et al. (2001) demonstrated that β -APP peptide 1-42 (β -APP42) couples to the MAPK cascade via α 7 nicotinic acetylcholine receptors (nAChR). *In vivo* elevation of β -APP, such as that exhibited in animal models for AD, leads to the upregulation of α 7-nAChR protein. This upregulation occurred concomitantly with the down-regulation of MAPK^{ERK2} in hippocampi of aged animals (Dineley et al., 2001).

The phosphorylation state of a transcriptional mediator of long-term potentiation and a downstream target of the MAPK^{ERK} cascade, CREB protein, were affected also, supporting the model that derangement of hippocampus signal transduction cascades in AD arises as a consequence of increased β -APP burden and chronic activation of MAPK^{ERK} in an α 7-nAChR-dependent manner that eventually leads to the down-regulation of MAPK^{ERK2} and decreased phosphorylation of CREB protein. Potential pathways involving cell death-related cofactors and AD are schematized in Fig. 5.

4.5. Redox/oxidative mechanisms and MAPK-mediated *Tau* phosphorylation

Oxidative stress play a major role on the pathogenesis of AD (Chen et al., 2003; de la Monte et al., 2000; Floyd, 1999; Tamagno et al., 2003). For example, increased expression of heme oxygenase-1 (HO-1) is a common feature in a number of neuro-degenerative diseases, including AD (Floyd, 1999; Haddad, 2002d; Haddad, 2003; Haddad, 2006; Haddad and Land, 2000a; Haddad and Land, 2000b; Haddad et al., 2000; Takeda et al., 2000; Zhang and Jope, 1999). Interestingly, the spatial distribution of HO-1 expression in diseased brain is essentially identical to that of pathological expression of *Tau*.




Figure 5: A diagrammatic scheme showing potential caspase/apoptosis pathways in the development of AD due to chronic injury caused by the excessive deposition of β -APP and NFT. AD, Alzheimer's; APP, Amyloid precursor protein; ER, Endoplasmic reticulum; NFT, Neurofibrillary tangle; PHF, Paired helical formation.

The relationship between HO-1 and *Tau* was explored, using neuroblastoma cells stably transfected with sense and antisense HO-1 constructs, as well as with the vector alone. In transfected cells over-expressing HO-1, the activity of heme oxygenase was increased, and conversely, the level of *Tau* protein was dramatically decreased, when compared with antisense HO-1 or CEP transfected cells (Haddad, 2002c; Haddad, 2002d; Takeda et al., 2000). The suppression of *Tau* protein expression was almost completely reversed by zinc-deuteroporphyrin, a specific inhibitor of HO activity. The activated forms of MAPK^{ERK} were also decreased in cells over-

expressing HO-1, although no changes in the expression of total $\text{MAPK}^{\text{ERK1/2}}$ proteins were observed (Takeda et al., 2000).

These data are in agreement with the finding that the expression of *Tau* is regulated through signal cascades including the MAPK^{ERK} , whose activities are modulated by oxidative stresses (Fig. 6). The expression of *Tau* and HO-1, then, may be regulated by oxidative stresses (Haddad, 2002b; Haddad, 2002c) in a coordinated manner and play a pivotal role in the cytoprotection of neuronal cells (Pei et al., 2003).




Figure 6: The role of selective MAPKs, mitogenic stimuli and oxidative stress in the development and evolution of AD.

4.6. Inflammatory mediators and MAPK-mediated Tau phosphorylation

Inflammatory mediators (Haddad, 2002d; Haddad, 2002e; Haddad and Harb, 2005a; Haddad and Harb, 2005b) have been implicated in the pathophysiology of neuro-degenerative diseases, including AD (Paris et al., 2003; Xia and Hyman, 2002). For instance, the chemokine receptor CXCR3 and its ligand, IP-10, were detected in AD brains (Xia et al., 2000). CXCR3 was detected constitutively on neurons and neuronal processes in various cortical and sub-cortical regions; IP-10 was observed in a subpopulation of astrocytes in normal brain and was markedly elevated in astrocytes in AD brains. Many IP-10⁺ astrocytes were also associated with senile plaques and had an apparently coordinated upregulation of MIP-1 β (Xia et al., 2000). Moreover, it was shown that CXCR3 ligands, IP-10

and Mig, were able to activate MAPK^{ERK1/2} pathway in mouse cortical neurons, suggesting a novel mechanism of neuronal-glia interaction.

Similarly, one of the CXCR2 ligands GRO- α /KC can be a potent trigger for the MAPK^{ERK1/2} and PI-3 kinase pathways, as well as *Tau* hyperphosphorylation in the mouse primary cortical neurons (Xia and Hyman, 2002). GRO- α immunoreactivity can be also detected in a subpopulation of neurons in normal and AD. Therefore, the CXCR2-ligand pair may have a potent pathophysiological role in neuro-degenerative diseases.

In concert with this, reactive microglia have been suggested to play a role in AD process, and previous

studies have shown that expression of CD45, a membrane-bound protein-tyrosine phosphatase (PTP), is elevated in microglia in AD brains (Tan et al., 2000). To investigate the possible role of CD45 in microglial responsiveness to β -APP, primary cultured microglia were co-treated with a tyrosine phosphatase inhibitor [potassium bisperoxo (1,10-phenanthroline) oxovanadate (phen), 5 micrometer] and freshly solubilized β -APP peptides (1000 nm). Data showed synergistic induction of microglial activation as evidenced by TNF- α production and nitric oxide (NO) release, both of which were dependent on the activation of MAPK^{ERK1/2}. Furthermore, co-treatment with phen and β -APP peptides resulted in microglia-induced neuronal cell injury (Fig. 5). Stimulation of microglial CD45 by anti-CD45 antibody markedly inhibited these effects via inhibition of MAPK^{ERK1/2}, suggesting that CD45 is a negative regulator of microglial activation (Tan et al., 2000). Accordingly, primary cultured microglia from CD45-deficient mice demonstrated hyper-responsiveness to β -APP, as evidenced by TNF- α release, NO production and neuronal injury after stimulation with β -APP peptides.

As a validation of these findings *in vivo*, brains from a transgenic mouse model of AD [transgenic Swedish APP-over-expressing (Tg APP(Sw)) mice] deficient for CD45 demonstrated markedly increased production of TNF- α , compared with Tg APP(Sw) mice (Chong et al. 2001; Smits et al., 2001; Tan et al., 2000; Tomidokoro et al., 2001; Del Villar and Miller, 2004). Taken together, these results suggested that therapeutic agents that stimulate the CD45/PTP signaling pathway might be effective in suppressing microglial activation associated with AD.

Moreover, a similar mechanism has been proposed for IL-1. For instance, activated MAPK^{p38} and IL-1 have both been implicated in the hyper-phosphorylation of *Tau* (Sheng et al., 2001). This, together with findings showing that IL-1 activates MAPK^{p38} *in vitro* and is markedly over-expressed in AD brain, suggested a role for IL-1-induced MAPK^{p38} activation in the genesis of NFT in AD. Frequent co-localization of hyper-phosphorylated *Tau* protein (AT8 antibody) and activated MAPK^{p38} in neurons and in dystrophic neurites in AD and frequent association of these structures with activated microglia over-expressing IL-1 were reported (Sheng et al., 2001). Tissue levels of IL-1 mRNA as well as of both phosphorylated and

non-phosphorylated isoforms of *Tau* were elevated in those brains.

Furthermore, significant correlations were found between the numbers of AT8- and MAPK^{p38}-immunoreactive neurons, and between the numbers of activated microglia over-expressing IL-1 and the numbers of both AT8- and MAPK^{p38}-immunoreactive neurons. In addition, rats bearing IL-1-impregnated pellets showed a six- to seven-fold increase in the levels of MAPK^{p38} mRNA, compared with rats with vehicle-only pellets (Sheng et al., 2001). These results suggested that microglial activation and IL-1 overexpression are part of a feedback cascade in which MAPK^{p38} overexpression and activation leads to *Tau* hyper-phosphorylation and NFT pathology in AD (Atzori et al., 2001; Daniels et al., 2001; Ferrer et al., 2001; Williamson et al., 2002; Hoozemans et al., 2004). More recently, IL-6 was also reported to induce Alzheimer-type phosphorylation of *Tau* protein by deregulating the cdk5/p35 pathway (Quintanilla et al., 2004).

5. Summary, conclusions and future prospects

There are multiple lines of evidence showing that oxidative stress (Haddad, 2004a; Haddad, 2004b) and aberrant mitogenic signaling (Zhu et al., 2002) play an important role in the pathogenesis of AD (Churcher, 2006; Haddad and Land, 2000a; Haddad and Land, 2000b; Haddad et al., 2000; Zhu et al., 2001a; 2001b) (Fig. 6). However, the chronological relationship between these and other events associated with disease pathogenesis is not strictly elucidated. Given the crucial role that MAPK pathways play in mitogenic signaling (MAPK^{ERK}) and cellular stress signaling (MAPK^{JNK/SAPK} and MAPK^{p38}), the chronological and spatial relationship between activated MAPKs during disease progression is warranted (Savage et al., 2002; Taru et al., 2002). While all three kinases are activated in the same susceptible neurons in mild and severe cases, in non-demented cases with limited pathology, both MAPK^{ERK} and MAPK^{JNK} are activated but MAPK^{p38} is not (Ferrer et al., 2005). However, in non-demented cases lacking any sign of pathology, either MAPK^{ERK} alone or MAPK^{JNK} alone can be activated, indicating that MAPK pathways are differentially activated during the course of AD and, by inference, suggesting that both oxidative stress/inflammatory and abnormalities in mitotic signaling can independently serve to initiate, but both are necessary to propagate,

disease pathogenesis (Daniels et al., 2001; Koistinaho et al., 2002).

The complex molecular interactions between MAPKs and proteins (plagues) associated with the evolution of AD form a cornerstone in the knowledge of a burgeoning field of neurodegenerative, inflammatory diseases and ageing (Ho et al., 2005). MAPKs, therefore, may constitute a neurogenetic, therapeutic target for the diagnosis of a preventative medical strategy for early detection, and possible treatment, of Alzheimer's.

Acknowledgments

The author would like to appreciate the comments of his colleagues at UCSF (USA) and AUB (Lebanon) for constructive criticism. This manuscript was written while the author was a research fellow at UCSF. Some of the reproduced figures, with the exception of Fig. 3, were adapted with modifications courtesy of authored and co-authored references therein cited. John Haddad held the Georges John Livanos prize (London) and the NIH (UCSF) award fellowship. The author's own publications are, in part, financially supported by the Anonymous Trust (Scotland), the National Institute for Biological Standards and Control (England), the Tenovus Trust (Scotland), the UK Medical Research Council (MRC, London), the Wellcome Trust (London) (Tayside Institute of Child Health, Ninewells Hospital and Medical School, University of Dundee, Scotland, UK), and the National Institutes of Health (Department of Anesthesia and Perioperative Care, University of California at San Francisco, California, USA).

Abbreviations

Alzheimer's disease, AD; β -Amyloid precursor protein, β -APP; Calmodulin, CaM; Calyculin, CAL; cAMP-response element binding protein, CREB; Cyclin-dependent kinase, cdk; Early-onset familial AD, EOFAD; Epidermal growth factor, EGF; EGF receptor threonine kinase, ERT kinase; Extracellular receptor kinase, ERK; Fluorescence resonance energy transfer, FRET; Glutathione S-transferase Pi, GSTp; Glycogen synthase kinase, GSK; GTPase activating protein, GAP; Guanine nuclear exchange factor, GEF; Heme oxygenase, HO; Human embryonic kidney, HEK; Interleukin, IL; Jun N-terminal kinase, JNK; JNK-interacting protein, JIP; *N*-Methyl-D-aspartate, NMDA; Microtubule associated protein, MAP; MAP

kinase phosphatase, MKP; Mitogen-activated protein kinase, MAPK; MAP kinase kinase kinase, MAPKKK; MAP kinase kinase, MAPKK; Mixed lineage kinase, MLK; Myelin basic protein, MBP; Nerve growth factor, NGF; Neurofibrillary tangles, NFT; Nicotinic acetylcholine receptors, nAChR; Nitric oxide, NO; Okadaic acid, OKA; Paired helical filament PHF; Phorbol 12-myristate 13-acetate, PMA; Phosphatidylinositol 3 kinase, PI3-K; Platelet-derived growth factor, PDGF; Presenilin, PS; Protein kinase A, PKA; Protein kinase C, PKC; Protein phosphatase, PP; Protein tyrosine kinase, PTK; Protein-tyrosine phosphatase, PTP; Reactive oxygen species, ROS; Receptor for advanced glycosylated end products, RAGE; Receptor tyrosine kinase, RTK; Ribosomal S6 protein kinase, RSK; Serum response factor, SRF; Stress-activated protein kinase, SAPK; *Tau* protein kinase, TPK; Transforming growth factor, TGF; Tumor necrosis factor, TNF.

References

- Abe, K., Saito, H., 2000. Amyloid β neuro-toxicity not mediated by the mitogen-activated protein kinase cascade in cultured rat hippocampal and cortical neurons. *Neurosci. Lett.* 292, 1-4.
- Akhand, A.A., Du, J., Liu, W., Hossain, K., Miyata, T., Nagase, F., Kato, M., Suzuki, H., Nakashima, I., 2002. Redox-linked cell surface-oriented signaling for T-cell death. *Antioxid. Redox Signal.* 4, 445-454.
- Anderson, V.C., Litvack, Z.N., Kaye, J.A., 2005. Magnetic resonance approaches to brain aging and Alzheimer disease-associated neuropathology. *Top. Magn. Reson. Imaging* 16, 439-452.
- Anderton, B.H., Betts, J., Blackstock, W.P., Brion, J.P., Chapman, S., Connell, J., Dayanandan, R., Gallo, J.M., Gibb, G., Hanger, D.P., Hutton, M., Kardalinos, E., Leroy, K., Lovestone, S., Mack, T., Reynolds, C.H., Van Slegtenhorst, M., 2001. Sites of phosphorylation in *Tau* and factors affecting their regulation. *Biochem. Soc. Symp.* 67, 73-80.
- Angulo, E., Casado, V., Mallol, J., Canela, E.I., Vinals, F., Ferrer, I., Lluís, C., Franco, R., 2003. A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. *Brain Pathol.* 13, 440-451.

- Aplin, A.E., Gibb, G.M., Jacobsen, J.S., Gallo, J.M., Anderton, B.H., 1996. *In vitro* phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3 β . *J. Neurochem.* 67, 699-707.
- Atzori, C., Ghetti, B., Piva, R., Srinivasan, A.N., Zolo, P., Delisle, M.B., Mirra, S.S., Migheli, A., 2001. Activation of the JNK/p38 pathway occurs in diseases characterized by *Tau* protein pathology and is related to *Tau* phosphorylation but not to apoptosis. *J. Neuropathol. Exp. Neurol.* 60, 1190-1197.
- Avruch, J., Khokhlatchev, A., Kyriakis, J.M., Luo, Z., Tzivion, G., Vavvas, D., Zhang, X.F., 2001. Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade. *Recent Prog. Horm. Res.* 56, 127-155.
- Bardwell, L., 2006. Mechanisms of MAPK signalling specificity. *Biochem. Soc. Trans.* 34, 837-841.
- Barr, R.K., Bogoyevitch, M.A., 2001. The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). *Int. J. Biochem. Cell Biol.* 33, 1047-1063.
- Baum, L., Seger, R., Woodgett, J.R., Kawabata, S., Maruyama, K., Koyama, M., Silver, J., Saitoh, T., 1995. Over-expressed *Tau* protein in cultured cells is phosphorylated without formation of PHF: Implication of phospho-protein phosphatase involvement. *Brain Res. Mol. Brain Res.* 34, 1-17.
- Beardsley, T., 1993. Unraveling Alzheimer's: A major cause of the disease yields to researchers. *Sci. Am.* 269, 28-31.
- Beardsley, T., 1995. Putting Alzheimer's to the tests: Several new techniques may detect the disease. *Sci. Am.* 272, 12-13.
- Belcheva, M.M., Coscia, C.J., 2002. Diversity of G protein-coupled receptor signaling pathways to ERK/MAP kinase. *Neurosignals* 11, 34-44.
- Bendinelli, P., Piccoletti, R., Maroni, P., Bernelli-Zazzera, A., 1995. The liver response to *in vivo* heat shock involves the activation of MAP kinases and RAF and the tyrosine phosphorylation of Shc proteins. *Biochem. Biophys. Res. Commun.* 216, 54-61.
- Bi, R., Broutman, G., Foy, M.R., Thompson, R.F., Baudry, M., 2000. The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. *Proc. Natl. Acad. Sci. USA* 97, 3602-3607.
- Blanchard, B.J., devi Raghunandan, R., Roder, H.M., Ingram, V.M., 1994. Hyper-phosphorylation of human *Tau* by brain kinase PK-40^{ERK} beyond phosphorylation by cAMP-dependent PKA: Relation to Alzheimer's disease. *Biochem. Biophys. Res. Commun.* 200, 187-194.
- Blennow, K., de Leon, M.J., Zetterberg, H., 2006. Alzheimer's disease. *Lancet* 368, 387-403.
- Bulavin, D.V., Amundson, S.A., Fornace, A.J., 2002. p38 and Chk1 kinases: Different conductors for the G(2)/M checkpoint symphony. *Curr. Opin. Genet. Dev.* 12, 92-97.
- Burnham, L., 1988. Alzheimer's proteins. *Sci. Am.* 258, 23-24.
- Canet-Aviles, R.M., Anderton, M., Hooper, N.M., Turner, A.J., Vaughan, P.F., 2002. Muscarine enhances soluble amyloid precursor protein secretion in human neuroblastoma SH-SY5Y by a pathway dependent on protein kinase C(alpha), src-tyrosine kinase and extracellular signal-regulated kinase but not phospholipase C. *Brain Res. Mol. Brain Res.* 102, 62-72.
- Cano, E., Mahadevan, L.C., 1995. Parallel signal processing among mammalian MAPKs. *Trends Biochem. Sci.* 20, 117-122.
- Cazaubon, S.M., Ramos-Morales, F., Fischer, S., Schweighoffer, F., Strosberg, A.D., Couraud, P.O., 1994. Endothelin induces tyrosine phosphorylation and GRB2 association of Shc in astrocytes. *J. Biol. Chem.* 269, 24805-24809.
- Chakraborty, P., 2001. G-protein-mediated signaling and its control in macrophages and mammalian cells. *Crit. Rev. Microbiol.* 27, 1-8.
- Chattopadhyay, N., Brown, E.M., 2000. Cellular "sensing" of extracellular calcium (Ca²⁺_o): Emerging roles in regulating diverse physiological functions. *Cell. Signal.* 12, 361-366.

- Chen, Y., Grall, D., Salcini, A.E., Pelicci, P.G., Pouyssegur, J., Van Obberghen-Schilling, E., 1996. Shc adaptor proteins are key transducers of mitogenic signaling mediated by the G protein-coupled thrombin receptor. *EMBO J.* 15, 1037-1044.
- Chen, G.J., Xu, J., Lahousse, S.A., Caggiano, N.L., de la Monte, S.M., 2003. Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. *J. Alzheimers Dis.* 5, 209-228.
- Chong, Y.H., Sung, J.H., Shin, S.A., Chung, J.H., Suh, Y.H., 2001. Effects of the β -amyloid and carboxyl-terminal fragment of Alzheimer's amyloid precursor protein on the production of the tumor necrosis factor- α and matrix metalloproteinase-9 by human monocytic THP-1. *J. Biol. Chem.* 276, 23511-23517.
- Churcher, I., 2006. Tau therapeutic strategies for the treatment of Alzheimer's disease. *Curr. Top. Med. Chem.* 6, 579-595.
- Cobb, M.H., Xu, S., Hepler, J.E., Hutchison, M., Frost, J., Robbins, D.J., 1994. Regulation of the MAP kinase cascade. *Cell. Mol. Biol. Res.* 40, 253-256.
- Courtneidge, S.A., Fumagalli, S., Koegl, M., Superti-Furga, G., Twamley-Stein, G.M., 1993. The Src family of protein tyrosine kinases: regulation and functions. *Dev. Suppl.* 1, 57-64.
- Cuenda, A., 2000. Mitogen-activated protein kinase kinase 4 (MKK4). *Int. J. Biochem. Cell Biol.* 32, 581-587.
- Cullen, P.J., Lockyer, P.J., 2002. Integration of calcium and Ras signalling. *Nat. Rev. Mol. Cell Biol.* 3, 339-348.
- Dalrymple, S.A., 2002. p38 mitogen activated protein kinase as a therapeutic target for Alzheimer's disease. *J. Mol. Neurosci.* 19, 295-299.
- Daniels, W.M., Hendricks, J., Salie, R., Taljaard, J.J., 2001. The role of the MAP-kinase superfamily in beta-amyloid toxicity. *Metab. Brain Dis.* 16, 175-185.
- Daulhac, L., Kowalski-Chauvel, A., Pradayrol, L., Vaysse, N., Seva, C., 1997. Ca^{2+} and protein kinase C-dependent mechanisms involved in gastrin-induced Shc/Grb2 complex formation and P44-mitogen-activated protein kinase activation. *Biochem. J.* 325, 383-389.
- Davis, R.J., 2000. Signal transduction by the JNK group of MAP kinases. *Cell* 103, 239-252.
- de la Monte, S.M., Ganju, N., Feroz, N., Luong, T., Banerjee, K., Cannon, J., Wands, J.R., 2000. Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells. *J. Alzheimers Dis.* 2, 261-281.
- Del Villar, K., Miller, C.A., 2004. Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons. *Proc. Natl. Acad. Sci. U. S. A.* 101, 4210-4215.
- Denhardt, D.T., 1996. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: The potential for multiplex signalling. *Biochem. J.* 318, 729-747.
- Dhanasekaran, N., Dermott, J.M., 1996. Signaling by the G12 class of G proteins. *Cell. Signal.* 8, 235-245.
- Dickens, M., Rogers, J.S., Cavanagh, J., Raitano, A., Xia, Z., Halpern, J.R., Greenberg, M.E., Sawyers, C.L., Davis, R.J., 1997. A cytoplasmic inhibitor of the JNK signal transduction pathway. *Science* 277, 693-696.
- Dickey, C.A., Petrucelli, L., 2006. Current strategies for the treatment of Alzheimer's disease and other tauopathies. *Expert Opin. Ther. Targets* 10, 665-676.
- Dineley, K.T., Westerman, M., Bui, D., Bell, K., Ashe, K.H., Sweatt, J.D., 2001. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal $\alpha 7$ nicotinic acetylcholine receptors: *In vitro* and *in vivo* mechanisms related to Alzheimer's disease. *J. Neurosci.* 21, 4125-4133.
- Dong, C., Davis, R.J., Flavell, R.A., 2001. Signaling by the JNK group of MAP kinases: c-Jun N-terminal Kinase. *J. Clin. Immunol.* 21, 253-257.
- Drachman, D.A., 2006. Aging of the brain, entropy, and Alzheimer disease. *Neurology* 67, 1340-1352.

- Ekinci, F.J., Shea, T.B., 1999. Hyper-activation of mitogen-activated protein kinase increases phospho-*Tau* immunoreactivity within human neuroblastoma: Additive and synergistic influence of alteration of additional kinase activities. *Cell. Mol. Neurobiol.* 19, 249-260.
- Ekinci, F.J., Malik, K.U., Shea, T.B., 1999. Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to β -amyloid. MAP kinase mediates β -amyloid-induced neuro-degeneration. *J. Biol. Chem.* 274, 30322-30327.
- English, J.M., Cobb, M.H., 2002. Pharmacological inhibitors of MAPK pathways. *Trends Pharmacol. Sci.* 23, 40-45.
- English, J., Pearson, G., Wilsbacher, J., Swantek, J., Karandikar, M., Xu, S., Cobb, M.H., 1999. New insights into the control of MAP kinase pathways. *Exp. Cell Res.* 253, 255-270.
- Enslin, H., Raingeaud, J., Davis, R.J., 1998. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. *J. Biol. Chem.* 273, 1741-1748.
- Erickson, D., 1991. Model mice: Transgenic animals and Alzheimer's research. *Sci. Am.* 265, 34.
- Erickson, A.K., Payne, D.M., Martino, P.A., Rossomando, A.J., Shabanowitz, J., Weber, M.J., Hunt, D.F., Sturgill, T.W., 1990. Identification by mass spectrometry of threonine 97 in bovine myelin basic protein as a specific phosphorylation site for mitogen-activated protein kinase. *J. Biol. Chem.* 265, 19728-19735.
- Errede, B., Cade, R.M., Yashar, B.M., Kamada, Y., Levin, D.E., Irie, K., Matsumoto, K., 1995. Dynamics and organization of MAP kinase signal pathways. *Mol. Reprod. Dev.* 42, 477-485.
- Ferrer, I., Blanco, R., Carmona, M., Puig, B., 2001. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in *Tau* deposits in neurons and glial cells in tauopathies. *J. Neural. Transm.* 108, 1397-1415.
- Ferrer, I., Gomez-Isla, T., Puig, B., Freixes, M., Ribe, E., Dalfo, E., Avila, J., 2005. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. *Curr. Alzheimer Res.* 2, 3-18.
- Fleming, Y., Armstrong, C.G., Morrice, N., Paterson, A., Goedert, M., Cohen, P., 2000. Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. *Biochem. J.* 352, 145-154.
- Floyd, R.A., 1999. Antioxidants, oxidative stress, and degenerative neurological disorders. *Proc. Soc. Exp. Biol. Med.* 222, 236-245.
- Frye, R.A., 1992. Involvement of G proteins, cytoplasmic calcium, phospholipases, phospholipid-derived second messengers, and protein kinases in signal transduction from mitogenic cell surface receptors. *Cancer Treat. Res.* 63, 281-299.
- Gadea, G., Lapasset, L., Gauthier-Rouviere, C., Roux, P., 2002. Regulation of Cdc42-mediated morphological effects: a novel function for p53. *EMBO J.* 21, 2373-2382.
- Ganju, P., O'Bryan, J.P., Der, C., Winter, J., James, I.F., 1998. Differential regulation of SHC proteins by nerve growth factor in sensory neurons and PC12 cells. *Eur. J. Neurosci.* 10, 1995-2008.
- Garver, T.D., Oyler, G.A., Harris, K.A., Polavarapu, R., Damuni, Z., Lehman, R.A., Billingsley, M.L., 1995. *Tau* phosphorylation in brain slices: Pharmacological evidence for convergent effects of protein phosphatases on *Tau* and mitogen-activated protein kinase. *Mol. Pharmacol.* 47, 745-756.
- Ghribi, O., Prammonjago, P., Herman, M.M., Spaulding, N.K., Savory, J., 2003. Abeta(1-42)-induced JNK and ERK activation in rabbit hippocampus is differentially regulated by lithium but is not involved in the phosphorylation of tau. *Brain Res. Mol. Brain Res.* 119, 201-206.

- Giannakopoulos, P., Gold, G., Kovari, E., von Gunten, A., Imhof, A., Bouras, C., Hof, P.R., 2007. Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. *Acta Neuropathol. (Berl.)* 113, 1-12.
- Grant, S.M., Morinville, A., Maysinger, D., Szyf, M., Cuello, A.C., 1999. Phosphorylation of mitogen-activated protein kinase is altered in neuro-ectodermal cells over-expressing the human amyloid precursor protein 751 isoform. *Brain Res. Mol. Brain Res.* 72, 115-120.
- Greenberg, S.M., Koo, E.H., Selkoe, D.J., Qiu, W.Q., Kosik, K.S., 1994. Secreted beta-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances *Tau* phosphorylation. *Proc. Natl. Acad. Sci. USA* 91, 7104-7108.
- Guan, K.L., 1994. The mitogen activated protein kinase signal transduction pathway: From the cell surface to the nucleus. *Cell. Signal.* 6, 581-589.
- Guha, M., Mackman, N., 2001. LPS induction of gene expression in human monocytes. *Cell. Signal.* 13, 85-94.
- Guisse, S., Braguer, D., Carles, G., Delacourte, A., Briand, C., 2001. Hyper-phosphorylation of *Tau* is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells. *J. Neurosci. Res.* 63, 257-267.
- Haddad, J.J., 2001. VX-745: Vertex Pharmaceuticals. *Curr. Opin. Investig. Drugs* 2, 1070-1076.
- Haddad, J.J., 2002a. The involvement of L - γ -glutamyl- L -cysteinyl-glycine (glutathione/GSH) in the mechanism of redox signaling mediating MAPK^{p38}-dependent regulation of pro-inflammatory cytokine production. *Biochem. Pharmacol.* 63, 305-320.
- Haddad J.J., 2002b. Oxygen homeostasis, thiol equilibrium and redox regulation of signaling transcription factors in the alveolar epithelium. *Cell. Signal.* 14, 799-810.
- Haddad J.J., 2002c. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. *Cell. Signal.* 14, 879-897.
- Haddad J.J., 2002d. Pharmaco-redox regulation of cytokine-related pathways: From receptor signaling to pharmacogenomics. *Free Radic. Biol. Med.* 33, 907-926.
- Haddad J.J., 2002e. Cytokines and related receptor-mediated signaling pathways. *Biochem. Biophys. Res. Commun.* 297, 700-713.
- Haddad J.J., 2002f. Redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury. I. Role for nuclear factor- κ B. *Crit. Care* 6, 481-490.
- Haddad J.J., 2003. Redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury. II. Role for hypoxia-inducible factor-1 α . *Crit. Care* 7, 47-54.
- Haddad J.J., 2004a. Redox and oxidant-mediated regulation of apoptosis signaling pathways: immunopharmaco-redox conception of oxidative siege versus cell death commitment. *Int. Immunopharmacol.* 4, 475-493.
- Haddad, J.J., 2004b. Oxygen sensing and oxidant/redox-related pathways. *Biochem. Biophys. Res. Commun.* 316, 969-977.
- Haddad, J.J., 2005. N-methyl-D-aspartate (NMDA) and the regulation of mitogen-activated protein kinase (MAPK) signaling pathways: a revolving neurochemical axis for therapeutic intervention? *Prog. Neurobiol.* 77, 252-282.
- Haddad, J.J., 2007. Brain hypoxia up-regulates the phosphorylation of MAPK^{ERK} independent of MAPK^{p38}: Involvement of a pro-apoptotic, Bax-sensitive pathway with hypoxia/reoxygenation in anoxia-tolerant turtle, *Chrysemys picta bellii*. *Int. J. Mol. Med. Adv. Sci.*, In press.
- Haddad J.J., Land S.C., 2000a. O₂-evoked regulation of HIF-1 α and NF- κ B in perinatal lung epithelium requires glutathione biosynthesis. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 278, L492-L503.
- Haddad J.J., Land S.C., 2000b. The differential expression of apoptosis factors in the alveolar epithelium is redox sensitive and requires NF- κ B

- (RelA)-selective targeting. *Biochem. Biophys. Res. Commun.* 271, 257-267.
- Haddad, J.J., Land, S.C., 2002. Redox/ROS regulation of lipopolysaccharide-induced mitogen-activated protein kinase (MAPK) activation and MAPK-mediated TNF- α biosynthesis. *Br. J. Pharmacol.* 135, 520-536.
- Haddad J.J., Fahlman C.S., 2002. Redox and oxidant-mediated regulation of interleukin-10: An anti-inflammatory, antioxidant cytokine? *Biochem. Biophys. Res. Commun.* 297, 163-176.
- Haddad, J.J., Harb, H.L., 2005a. L- γ -Glutamyl-L-cysteinyl-glycine (glutathione; GSH) and GSH-related enzymes in the regulation of pro- and anti-inflammatory cytokines: a signaling transcriptional scenario for redox(y) immunologic sensor(s)? *Mol. Immunol.* 42, 987-1014.
- Haddad, J.J., Harb, H.L., 2005b. Cytokines and the regulation of hypoxia-inducible factor (HIF)-1 α . *Int. Immunopharmacol.* 5, 461-483.
- Haddad J.J., Olver R.E., Land S.C., 2000. Antioxidant/pro-oxidant equilibrium regulates HIF-1 α and NF- κ B redox sensitivity: Evidence for inhibition by glutathione oxidation in alveolar epithelial cells. *J. Biol. Chem.* 275, 21130-21139.
- Haddad, J.J., Saadé N.E., Safieh-Garabedian B., 2002. Cytokines and neuro-immune-endocrine interactions: A role for the hypothalamic-pituitary-adrenal revolving axis. *J. Neuroimmunol.* 133, 1-19.
- Haddad J.J., Saadé N.E., Safieh-Garabedian B., 2003. Interleukin-10 and the regulation of mitogen-activated protein kinases: Are these signaling modules targets for the anti-inflammatory action of this cytokine? *Cell. Signal.* 15, 255-267.
- Hagemann, C., Blank, J.L., 2001. The ups and downs of MEK kinase interactions. *Cell. Signal.* 13, 863-875.
- Haneda, M., Sugimoto, T., Kikkawa, R., 1999. Mitogen-activated protein kinase phosphatase: A negative regulator of the mitogen-activated protein kinase cascade. *Eur. J. Pharmacol.* 365, 1-7.
- Harper, S.J., LoGrasso, P., 2001. Signalling for survival and death in neurones: The role of stress-activated kinases, JNK and p38. *Cell. Signal.* 13, 299-310.
- Hazzalin, C.A., Mahadevan, L.C., 2002. MAPK-regulated transcription: A continuously variable gene switch? *Nat. Rev. Mol. Cell Biol.* 3, 30-40.
- Herlaar, E., Brown, Z., 1999. p38 MAPK signaling cascades in inflammatory disease. *Mol. Med. Today* 5, 439-447.
- Higuchi, M., Iwata, N., Saido, T.C., 2005. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. *Biochim. Biophys. Acta* 1751, 60-67.
- Hindley, A., Kolch, W., 2002. Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. *J. Cell Sci.* 115, 1575-1581.
- Ho, D.T., Shayan, H., Murphy, T.H., 1997. Okadaic acid induces hyper-phosphorylation of *Tau* independently of mitogen-activated protein kinase activation. *J. Neurochem.* 68, 106-111.
- Ho, G.J., Drego, R., Hakimian, E., Masliah, E., 2005. Mechanisms of cell signaling and inflammation in Alzheimer's disease. *Curr. Drug Targets Inflamm Allergy* 4, 247-256.
- Holmes-McNary, M., 2002. Nuclear factor- κ B signaling in catabolic disorders. *Curr. Opin. Clin. Nutr. Metab. Care* 5, 255-263.
- Howe, A.K., Aplin, A.E., Juliano, R.L., 2002. Anchorage-dependent ERK signaling: Mechanisms and consequences. *Curr. Opin. Genet. Dev.* 12, 30-35.
- Hoozemans, J.J., Veerhuis, R., Rozemuller, A.J., Arendt, T., Eikelenboom, P., 2004. Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex. *Neurobiol. Dis.* 15, 492-499.
- Hwang, D.Y., Cho, J.S., Lee, S.H., Chae, K.R., Lim, H.J., Min, S.H., Seo, S.J., Song, Y.S., Song, C.W., Paik, S.G., Sheen, Y.Y., Kim, Y.K., 2004. Aberrant expressions of pathogenic phenotype in Alzheimer's

- diseased transgenic mice carrying NSE-controlled APPsw. *Exp. Neurol.* 186, 20-32.
- Hyman, B.T., Elvhage, T.E., Reiter, J., 1994. Extracellular signal regulated kinases. Localization of protein and mRNA in the human hippocampal formation in Alzheimer's disease. *Am. J. Pathol.* 144, 565-572.
- Ichijo, H., 1999. From receptors to stress-activated MAP kinases. *Oncogene* 18, 6087-6093.
- Iqbal, K., Grundke-Iqbal, I., 2006. Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. *J. Alzheimers Dis.* 9, 219-242.
- Inui, T., Shinomiya, N., Fukasawa, M., Kuranaga, N., Ohkura, S., Seki, S., 2001. Telomerase activation and MAPK pathways in regenerating hepatocytes. *Hum. Cell.* 14, 275-282.
- Ip, Y.T., Davis, R.J., 1998. Signal transduction by the c-Jun N-terminal kinase (JNK): From inflammation to development. *Curr. Opin. Cell Biol.* 10, 205-219.
- James, N.D., Davis, D.R., Sindon, J., Hanger, D.P., Brion, J.P., Miller, C.C., Rosenberg, M.P., Anderton, B.H., Propst, F., 1996. Neurodegenerative changes including altered *Tau* phosphorylation and neurofilament immunoreactivity in mice transgenic for the serine/threonine kinase Mos. *Neurobiol. Aging* 17, 235-241.
- Jenkins, S.M., Zinnerman, M., Garner, C., Johnson, G.V., 2000. Modulation of *Tau* phosphorylation and intracellular localization by cellular stress. *Biochem. J.* 345, 263-270.
- Jellinger, K.A., 2006. Alzheimer 100 - highlights in the history of Alzheimer research. *J. Neural. Transm.* 113, 1603-1623.
- Jones, M.K., Wang, H., Peskar, B.M., Levin, E., Itani, R.M., Sarfeh, I.J., Tarnawski, A.S., 1999. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. *Nat. Med.* 5, 1418-1423.
- Johnson, G.V., 2006. Tau phosphorylation and proteolysis: insights and perspectives. *J. Alzheimers Dis.* 9, 243-250.
- Johnson, G.V., Bailey, C.D. The p38 MAP kinase signaling pathway in Alzheimer's disease. *Exp. Neurol.* 183, 263-268.
- Kanaan S.A., Safieh-Garabedian B., Haddad J.J., Atweh S.F., Abdelnoor A.M., Jabbur S.J., Saadé N.E. 1997. Effects of various analgesic and anti-inflammatory drugs on endotoxin-induced hyperalgesia in rats and mice. *Pharmacology* 54, 285-297.
- Kennedy, J.S., Raab, M., Rudd, C.E., 1999. Signaling scaffolds in immune cells. *Cell. Calcium* 26, 227-235.
- Kim, I.J., Lee, K.W., Park, B.Y., Lee, J.K., Park, J., Choi, I.Y., Eom, S.J., Chang, T.S., Kim, M.J., Yeom, Y.I., Chang, S.K., Lee, Y.D., Choi, E.J., Han, P.L., 1999. Molecular cloning of multiple splicing variants of JIP-1 preferentially expressed in brain. *J. Neurochem.* 72, 1335-1343.
- Knowles, R.B., Chin, J., Ruff, C.T., Hyman, B.T., 1999. Demonstration by fluorescence resonance energy transfer of a close association between activated MAP kinase and neurofibrillary tangles: Implications for MAP kinase activation in Alzheimer disease. *J. Neuropathol. Exp. Neurol.* 58, 1090-1098.
- Koistinaho, M., Kettunen, M.I., Goldsteins, G., Keinanen, R., Salminen, A., Ort, M., Bures, J., Liu, D., Kauppinen, R.A., Higgins, L.S., Koistinaho, J., 2002. Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. *Proc. Natl. Acad. Sci. USA* 99, 1610-1615.
- Kolch, W., 2000. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. *Biochem. J.* 351, 289-305.
- Korneyev, A.Y., 1998. Stress-induced *Tau* phosphorylation in mouse strains with different brain Erk 1 + 2 immunoreactivity. *Neurochem. Res.* 23, 1539-1543.

- Kumar, S., McDonnell, P.C., Gum, R.J., Hand, A.T., Lee, J.C., Young, P.R., 1997. Novel homologues of CSBP/p38 MAP kinase: Activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. *Biochem. Biophys. Res. Commun.* 235, 533-538.
- Lee, J.C., Young, P.R., 1996. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. *J. Leukoc. Biol.* 59, 152-157.
- Lee, J.C., Kumar, S., Griswold, D.E., Underwood, D.C., Votta, B.J., Adams, J.L., 2000. Inhibition of p38 MAP kinase as a therapeutic strategy. *Immunopharmacology* 47, 185-201.
- Lee Jr, J.T., McCubrey, J.A., 2002. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. *Leukemia* 16, 486-507.
- Leppa, S., Bohmann, D., 1999. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. *Oncogene* 18, 6158-6162.
- Levin, E.R., 2002. Cellular functions of plasma membrane estrogen receptors. *Steroids* 67, 471-475.
- Lewis, T.S., Shapiro, P.S., Ahn, N.G., 1998. Signal transduction through MAP kinase cascades. *Adv. Cancer Res.* 74, 49-139.
- Li, Y., Liu, L., Barger, S.W., Mrak, R.E., Griffin, W.S., 2001. Vitamin E suppression of microglial activation is neuroprotective. *J. Neurosci. Res.* 66, 163-170.
- Liebmann, C., 2001. Regulation of MAP kinase activity by peptide receptor signaling pathway: Paradigms of multiplicity. *Cell. Signal.* 13, 777-785.
- Lopez-Illasaca, M., 1998. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. *Biochem. Pharmacol.* 56, 269-277.
- Lovestone, S., Reynolds, C.H., Latimer, D., Davis, D.R., Anderton, B.H., Gallo, J.M., Hanger, D., Mulot, S., Marquardt, B., Stabel, S., Woodgett, J.R., Miller, C.C.K., 1994. Alzheimer's disease-like phosphorylation of the microtubule-associated protein *Tau* by glycogen synthase kinase-3 in transfected mammalian cells. *Curr. Biol.* 4, 1077-1086.
- Lowes, V.L., Ip, N.Y., Wong, Y.H., 2002. Integration of signals from receptor tyrosine kinases and G protein-coupled receptors. *Neurosignals* 11, 5-19.
- Mandelkow, E.M., Biernat, J., Drewes, G., Steiner, B., Lichtenberg-Kraag, B., Wille, H., Gustke, N., Mandelkow, E., 1993. Microtubule-associated protein *Tau*, paired helical filaments, and phosphorylation. *Ann. NY Acad. Sci.* 695, 209-216.
- Mandelkow, E.M., Biernat, J., Drewes, G., Gustke, N., Trinczek, B., Mandelkow, E., 1995. *Tau* domains, phosphorylation and interactions with microtubules. *Neurobiol. Aging* 16, 355-362.
- Marshall, C.J., 1994. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. *Curr. Opin. Genet. Dev.* 4, 82-89.
- Marshall, M.S., 1995. Ras target proteins in eukaryotic cells. *FASEB J.* 9, 1311-1318.
- Martindale, D., 2002. Peeling plaque. Researchers remain optimistic about a vaccine against Alzheimer's. *Sci. Am.* 286, 18, 20.
- Marx, J., 2001. Neuroscience: New leads on the 'how' of Alzheimer's. *Science* 293, 2192-2194.
- Matsuda, S., Yasukawa, T., Homma, Y., Ito, Y., Niikura, T., Hiraki, T., Hirai, S., Ohno, S., Kita, Y., Kawasumi, M., Kouyama, K., Yamamoto, T., Kyriakis, J.M., Nishimoto, I., 2001. c-Jun N-terminal kinase (JNK)-interacting protein-1b/islet-brain-1 scaffolds Alzheimer's amyloid precursor protein with JNK. *J. Neurosci.* 21, 6597-6607.
- McCubrey, J.A., May, W.S., Duronio, V., Mufson, A., 2000. Serine/threonine phosphorylation in cytokine signal transduction. *Leukemia* 14, 9-21.
- McDonald, D.R., Bamberger, M.E., Combs, C.K., Landreth, G.E., 1998. β -Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP-1 monocytes. *J. Neurosci.* 18, 4451-4460.

- Meriin, A.B., Gabai, V.L., Yaglom, J., Shifrin, V.I., Sherman, M.Y., 1998. Proteasome inhibitors activate stress kinases and induce Hsp72: Diverse effects on apoptosis. *J. Biol. Chem.* 273, 6373-6379.
- Mielke, K., Herdegen, T., 2000. JNK and p38 stress kinases: Degenerative effectors of signal-transduction-cascades in the nervous system. *Prog. Neurobiol.* 61, 45-60.
- Mills, J., Reiner, P.B., 1999. Mitogen-activated protein kinase is involved in N-methyl-D-aspartate receptor regulation of amyloid precursor protein cleavage. *Neuroscience* 94, 1333-1338.
- Mordret, G., 1993. MAP kinase kinase: A node connecting multiple pathways. *Biol. Cell* 79, 193-207.
- Morgan, D., 2006. Immunotherapy for Alzheimer's disease. *J. Alzheimers Dis.* 9, 425-432.
- Morrison, D.K., 1995. Mechanisms regulating Raf-1 activity in signal transduction pathways. *Mol. Reprod. Dev.* 42, 507-514.
- Murayama, Y., Takeda, S., Yonezawa, K., Giambarella, U., Nishimoto, I., Ogata, E., 1996. Cell surface receptor function of amyloid precursor protein that activates Ser/Thr kinases. *Gerontology* 42, 2-11.
- Nakamura, T., Sanokawa, R., Sasaki, Y., Ayusawa, D., Oishi, M., Mori, N., 1996. N-Shc: A neural-specific adapter molecule that mediates signaling from neurotrophin/Trk to Ras/MAPK pathway. *Oncogene* 13, 1111-1121.
- Nakamura, T., Muraoka, S., Sanokawa, R., Mori, N., 1998. N-Shc and Sck, two neuronally expressed Shc adapter homologs: Their differential regional expression in the brain and roles in neurotrophin and Src signaling. *J. Biol. Chem.* 273, 6960-6967.
- Nakamura, T., Komiyama, M., Gotoh, N., Koizumi, S., Shibuya, M., Mori, N., 2002. Discrimination between phosphotyrosine-mediated signaling properties of conventional and neuronal Shc adapter molecules. *Oncogene* 21, 22-31.
- Noselli, S., 1998. JNK signaling and morphogenesis in *Drosophila*. *Trends Genet.* 14, 33-38.
- Noselli, S., Agnes, F., 1999. Roles of the JNK signaling pathway in *Drosophila* morphogenesis. *Curr. Opin. Genet. Dev.* 9, 466-472.
- Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R., Vassar, R., 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. *J. Neurosci.* 26, 10129-10140.
- Obata, T., Brown, G.E., Yaffe, M.B., 2000. MAP kinase pathways activated by stress: The p38 MAPK pathway. *Crit. Care Med.* 28, N67-N77.
- Okamoto, T., Takeda, S., Murayama, Y., Ogata, E., Nishimoto, I., 1995. Ligand-dependent G protein coupling function of amyloid transmembrane precursor. *J. Biol. Chem.* 270, 4205-4208.
- Okazawa, H., Estus, S., 2002. The JNK/c-Jun cascade and Alzheimer's disease. *Am. J. Alzheimers Dis. Other Demen.* 17, 79-88.
- Ono, K., Han, J., 2000. The p38 signal transduction pathway: Activation and function. *Cell. Signal.* 12, 1-13.
- Oth, C., Mendoza-Naranjo, A., Mujica, L., Zambrano, A., Concha, I.I., Maccioni, R.B., 2003. Modulation of the JNK and p38 pathways by cdk5 protein kinase in a transgenic mouse model of Alzheimer's disease. *Neuroreport* 14, 2403-2409.
- Paris, D., Humphrey, J., Quadros, A., Patel, N., Crescentini, R., Crawford, F., Mullan, M., 2003. Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. *Neurol. Res.* 25, 642-651.
- Parsons, J.T., Parsons, S.J., 1997. Src family protein tyrosine kinases: Cooperating with growth factor and adhesion signaling pathways. *Curr. Opin. Cell Biol.* 9, 187-192.
- Pawson, T., 1994. Tyrosine kinase signaling pathways. *Princess Takamatsu. Symp.* 24, 303-322.

- Pearson, G., Bumeister, R., Henry, D.O., Cobb, M.H., White, M.A., 2000. Uncoupling Raf-1 from MEK1/2 impairs only a subset of cellular responses to Raf activation. *J. Biol. Chem.* 275, 37303-6.
- Pearson, G., Robinson, F., Beers, Gibson, T., Xu, B.E., Karandikar, M., Berman, K., Cobb, M.H., 2001. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. *Endocr. Rev.* 22, 153-183.
- Peel, A.L., 2004. PKR activation in neurodegenerative disease. *J. Neuropathol. Exp. Neurol.*, 63, 97-105.
- Pei, J.J., Gong, C.X., An, W.L., Winblad, B., Cowburn, R.F., Grundke-Iqbal, I., Iqbal, K., 2003. Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. *Am. J. Pathol.* 163, 845-858.
- Peyssonnaud, C., Eychene, A., 2001. The Raf/MEK/ERK pathway: New concepts of activation. *Biol. Cell* 93, 53-62.
- Pierce, K.L., Luttrell, L.M., Lefkowitz, R.J., 2001. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. *Oncogene* 20, 1532-1539.
- Plyte, S., Majolini, M.B., Pacini, S., Scarpini, F., Bianchini, C., Lanfrancone, L., Pelicci, P., Baldari, C.T., 2000. Constitutive activation of the Ras/MAP kinase pathway and enhanced TCR signaling by targeting the Shc adaptor to membrane rafts. *Oncogene* 19, 1529-1537.
- Pursiheimo, J.P., Kieksi, A., Jalkanen, M., Salmivirta, M., 2002. Protein kinase A balances the growth factor-induced Ras/ERK signaling. *FEBS Lett.* 521, 157-164.
- Quintanilla, R.A., Orellana, D.I., Gonzalez-Billault, C., Maccioni, R.B., 2004. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. *Exp. Cell Res.* 295, 245-257.
- Raghunandan, R., Ingram, V.M., 1995. Hyperphosphorylation of the cytoskeletal protein *Tau* by the MAP-kinase PK40erk2: Regulation by prior phosphorylation with cAMP-dependent protein kinase A. *Biochem. Biophys. Res. Commun.* 215, 1056-1066.
- Rapoport, M., Ferreira, A., 2000. PD-98059 prevents neurite degeneration induced by fibrillar β -amyloid in mature hippocampal neurons. *J. Neurochem.* 74, 125-133.
- Ravichandran, K.S., 2001. Signaling via Shc family adapter proteins. *Oncogene* 20, 6322-6330.
- Ray, L.B., Sturgill, T.W., 1987. Rapid stimulation by insulin of a serine/threonine kinase in 3T3-L1 adipocytes that phosphorylates microtubule-associated protein 2 *in vitro*. *Proc. Natl. Acad. Sci. USA* 84, 1502-1506.
- Reynolds, C.H., Betts, J.C., Blackstock, W.P., Nebreda, A.R., Anderton, B.H., 2000. Phosphorylation sites on *Tau* identified by nano-electrospray mass spectrometry: Differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and p38, and glycogen synthase kinase-3 β . *J. Neurochem.* 74, 1587-1595.
- Rincon, M., 2001. MAP-kinase signaling pathways in T cells. *Curr. Opin. Immunol.* 13, 339-345.
- Rincon, M., Flavell, R.A., Davis, R.A., 2000. The JNK and p38 MAP kinase signaling pathways in T cell-mediated immune responses. *Free Radic. Biol. Med.* 28, 1328-1337.
- Roder, H.M., Eden, P.A., Ingram, V.M., 1993. Brain protein kinase PK-40^{ERK} converts *Tau* into a PHF-like form as found in Alzheimer's disease. *Biochem. Biophys. Res. Commun.* 193, 639-647.
- Roder, H.M., Hoffman, F.J., Schroder, W., 1995. Phosphatase resistance of ERK2 brain kinase PK40erk2. *J. Neurochem.* 64, 2203-2212.
- Roder, H.M., Fracasso, R.P., Hoffman, F.J., Witowsky, J.A., Davis, G., Pellegrino, C.B., 1997. Phosphorylation-dependent monoclonal *Tau* antibodies do not reliably report phosphorylation by extracellular signal-regulated kinase 2 at specific sites. *J. Biol. Chem.* 272, 4509-4515.

- Runden, E., Seglen, P.O., Haug, F.M., Ottersen, O.P., Wieloch, T., Shamloo, M., Laake, J.H., 1998. Regional selective neuronal degeneration after protein phosphatase inhibition in hippocampal slice cultures: Evidence for a MAP kinase-dependent mechanism. *J. Neurosci.* 18, 7296-7305.
- Samanta, M.K., Wilson, B., Santhi, K., Sampath Kumar, K.P., Suresh, B., 2006. Alzheimer disease and its management: a review. *Am. J. Ther.* 13, 516-526.
- Sato, N., Kamino, K., Tateishi, K., Satoh, T., Nishiwaki, Y., Yoshiiwa, A., Miki, T., Ogihara, T., 1997. Elevated amyloid β protein(1-40) level induces CREB phosphorylation at serine-133 via p44/42 MAP kinase (ERK1/2)-dependent pathway in rat pheochromocytoma PC-12 cells. *Biochem. Biophys. Res. Commun.* 232, 637-642.
- Savage, M.J., Lin, Y.G., Ciallella, J.R., Flood, D.G., Scott, R.W., 2002. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. *J. Neurosci.* 22, 3376-3385.
- Sebolt-Leopold, J.S., 2000. Development of anticancer drugs targeting the MAP kinase pathway. *Oncogene* 19, 6594-6599.
- Selkoe, D.J., 1991. Amyloid protein and Alzheimer's disease. *Sci. Am.* 265, 68-71, 74-6, 78.
- Schlesinger, T.K., Fanger, G.R., Yujiri, T., Johnson, G.L., 1998. The TAO of MEKK. *Front. Biosci.* 3, D1181-D1186.
- Schneider, A., Biernat, J., von Bergen, M., Mandelkow, E., Mandelkow, E.M., 1999. Phosphorylation that detaches *Tau* protein from microtubules (Ser-262, Ser-214) also protects it against aggregation into Alzheimer paired helical filaments. *Biochemistry* 38, 3549-3558.
- Shanavas, A., Papasozomenos, S.C., 2000. *Tau* kinases in the rat heat shock model: Possible implications for Alzheimer disease. *Proc. Natl. Acad. Sci. USA* 97, 14139-14144.
- Sheng, J.G., Jones, R.A., Zhou, X.Q., McGinness, J.M., Van Eldik, L.J., Mrak, R.E., Griffin, W.S., 2001. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: Potential significance for *Tau* protein phosphorylation. *Neurochem. Int.* 39, 341-348.
- Shin, J.E., Koh, J.Y., Mook-Jung, I., 1999. Presenilin 1 mediates protein kinase C dependent α -secretase derived amyloid precursor protein secretion and mitogen-activated protein kinase activation in presenilin 1 transfected human embryonic kidney 293 cell. *Neurosci. Lett.* 269, 99-102.
- Smits, H.A., de Vos, N.M., Wat, J.W., van der Bruggen, T., Verhoef, J., Nottet, H.S., 2001. Intracellular pathways involved in TNF- α and superoxide anion release by A β (1-42)-stimulated primary human macrophages. *J. Neuroimmunol.* 115, 144-151.
- Solano, D.C., Sironi, M., Bonfini, C., Solerte, S.B., Govoni, S., Racchi, M., 2000. Insulin regulates soluble amyloid precursor protein release via phosphatidylinositol 3 kinase-dependent pathway. *FASEB J.* 14, 1015-1022.
- Sontag, E., 2001. Protein phosphatase 2A: The Trojan Horse of cellular signaling. *Cell. Signal.* 13, 7-16.
- St George-Hyslop, P.H., 2000. Piecing together Alzheimer's. *Sci. Am.* 283, 76-83.
- Standen, C.L., Brownlees, J., Grierson, A.J., Kesavapany, S., Lau, K.F., McLoughlin, D.M., Miller, C.C., 2001. Phosphorylation of Thr-668 in the cytoplasmic domain of the Alzheimer's disease amyloid precursor protein by stress-activated protein kinase 1b (Jun N-terminal kinase-3). *J. Neurochem.* 76, 316-320.
- Stein, T.D., Johnson, J.A., 2003. Genetic programming by the proteolytic fragments of the amyloid precursor protein: somewhere between confusion and clarity. *Rev. Neurosci.* 14, 317-341.
- Sugden, P.H., Clerk, A., 1997. Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. *Cell. Signal.* 9, 337-351.
- Sun, A., Liu, M., Nguyen, X.V., Bing, G., 2003. P38 MAP kinase is activated at early stages in Alzheimer's disease brain. *Exp. Neurol.* 183, 394-405.

- Suram, A., Venugopal, C., Prakasam, A., Sambamurti, K., 2006. Genotoxicity in Alzheimer's disease: role of amyloid. *Curr. Alzheimer Res.* 3, 365-375.
- Takeda, A., Perry, G., Abraham, N.G., Dwyer, B.E., Kutty, R.K., Laitinen, J.T., Petersen, R.B., Smith, M.A., 2000. Over-expression of heme oxygenase in neuronal cells, the possible interaction with Tau. *J. Biol. Chem.* 275, 5395-5399.
- Tan, J., Town, T., Mori, T., Wu, Y., Saxe, M., Crawford, F., Mullan, M., 2000. CD45 opposes β -amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. *J. Neurosci.* 20, 7587-7594.
- Tanaka, T., Zhong, J., Iqbal, K., Trenkner, E., Grundke-Iqbal, I., 1998. The regulation of phosphorylation of *Tau* in SY5Y neuroblastoma cells: the role of protein phosphatases. *FEBS Lett.* 426, 248-254.
- Taru, H., Iijima, K., Hase, M., Kirino, Y., Yagi, Y., Suzuki, T., 2002. Interaction of Alzheimer's β -amyloid precursor family proteins with scaffold proteins of the JNK signaling cascade. *J. Biol. Chem.* 277, 20070-20078.
- Tian, X., Feig, L.A., 2001. Basis for signaling specificity difference between Sos and Ras-GRF guanine nucleotide exchange factors. *J. Biol. Chem.* 276, 47248-47256.
- Tibbles, L.A., Woodgett, J.R., 1999. The stress-activated protein kinase pathways. *Cell. Mol. Life Sci.* 55, 1230-1254.
- Tomidokoro, Y., Ishiguro, K., Harigaya, Y., Matsubara, E., Ikeda, M., Park, J.M., Yasutake, K., Kawarabayashi, T., Okamoto, K., Shoji, M., 2001. A β amyloidosis induces the initial stage of *Tau* accumulation in APP(Sw) mice. *Neurosci. Lett.* 299, 169-172.
- Trojanowski, J.Q., Mawal-Dewan, M., Schmidt, M.L., Martin, J., Lee, V.M., 1993. Localization of the mitogen activated protein kinase ERK2 in Alzheimer's disease neurofibrillary tangles and senile plaque neurites. *Brain Res.* 618, 333-337.
- Troy, C.M., Rabacchi, S.A., Xu, Z., Maroney, A.C., Connors, T.J., Shelanski, M.L., Greene, L.A., 2001. β -Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. *J. Neurochem.* 77, 157-164.
- Uhlhaas, P.J., Singer, W., 2006. Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. *Neuron* 52, 155-168.
- Vacratsis, P.O., Gallo, K.A., 2000. Zipper-mediated oligomerization of the mixed lineage kinase SPRK/MLK-3 is not required for its activation by the GTPase cdc 42 but is necessary for its activation of the JNK pathway. Monomeric SPRK L410P does not catalyze the activating phosphorylation of Thr258 of murine Mitogen-activated protein kinase kinase 4. *J. Biol. Chem.* 275, 27893-27900.
- Wang, L.H., Besirli, C.G., Johnson, E.M. Jr., 2004. Mixed-lineage kinases: a target for the prevention of neurodegeneration. *Annu. Rev. Pharmacol. Toxicol.*, 44, 451-474.
- Weinstein-Oppenheimer, C.R., Blalock, W.L., Steelman, L.S., Chang, F., McCubrey, J.A., 2000. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. *Pharmacol. Ther.* 88, 229-279.
- Weston, C.R., Davis, R.J., 2002. The JNK signal transduction pathway. *Curr. Opin. Genet. Dev.* 12, 14-21.
- Williamson, R., Scales, T., Clark, B.R., Gibb, G., Reynolds, C.H., Kellie, S., Bird, I.N., Varndell, I.M., Sheppard, P.W., Everall, I., Anderton, B.H., 2002. Rapid tyrosine phosphorylation of neuronal proteins including *Tau* and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. *J. Neurosci.* 22, 10-20.
- Wirhth, O., Weis, J., Kaye, R., Saido, T.C., Bayer, T.A., 2006. Age-dependent axonal degeneration in an Alzheimer mouse model. *Neurobiol. Aging* .In press.
- Wurtman, R.J., 1985. Alzheimer's disease. *Sci. Am.* 252, 62-66, 71-74.
- Xia, M.Q., Bacskai, B.J., Knowles, R.B., Qin, S.X., Hyman, B.T., 2000. Expression of the chemokine receptor CXCR3 on neurons and the elevated

- expression of its ligand IP-10 in reactive astrocytes: *In vitro* ERK1/2 activation and role in Alzheimer's disease. *J. Neuroimmunol.* 108, 227-235.
- Xia, M., Hyman, B.T., 2002. GRO α /KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for *Tau* hyper-phosphorylation: A role in Alzheimer's disease? *J. Neuroimmunol.* 122, 55-64.
- Yamaguchi, H., Ishiguro, K., Uchida, T., Takashima, A., Lemere, C.A., Imahori, K., 1996. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for *Tau* protein kinase (TPK) I/glycogen synthase kinase-3 β and cyclin-dependent kinase 5, a component of TPK II. *Acta. Neuropathol. (Berl.)* 92, 232-241.
- Yao, Z., Diener, K., Wang, X.S., Zukowski, M., Matsumoto, G., Zhou, G., Mo, R., Sasaki, T., Nishina, H., Hui, C.C., Tan, T.H., Woodgett, J.P., Penninger, J.M., 1997. Activation of stress-activated protein kinases/c-Jun N-terminal protein kinases (SAPKs/JNKs) by a novel mitogen-activated protein kinase kinase. *J. Biol. Chem.* 272, 32378-32383.
- Zhang, L., Jope, R.S., 1999. Oxidative stress differentially modulates phosphorylation of ERK, p38 and CREB induced by NGF or EGF in PC12 cells. *Neurobiol. Aging* 20, 271-278.
- Zhang, W., Chen, T., Wan, T., He, L., Li, N., Yuan, Z., Cao, X., 2000. Cloning of DPK, a novel dendritic cell-derived protein kinase activating the ERK1/ERK2 and JNK/SAPK pathways. *Biochem. Biophys. Res. Commun.* 274, 872-879.
- Zhao, W.Q., Feng, C., Alkon, D.L., 2003. Impairment of phosphatase 2A contributes to the prolonged MAP kinase phosphorylation in Alzheimer's disease fibroblasts. *Neurobiol. Dis.* 14, 458-469.
- Zhu, X., Rottkamp, C.A., Boux, H., Takeda, A., Perry, G., Smith, M.A., 2000. Activation of p38 kinase links *Tau* phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. *J. Neuropathol. Exp. Neurol.* 59, 880-888.
- Zhu, X., Castellani, R.J., Takeda, A., Nunomura, A., Atwood, C.S., Perry, G., Smith, M.A., 2001a. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: The 'two hit' hypothesis. *Mech. Ageing. Dev.* 123, 39-46.
- Zhu, X., Rottkamp, C.A., Hartzler, A., Sun, Z., Takeda, A., Boux, H., Shimohama, S., Perry, G., Smith, M.A., 2001b. Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. *J. Neurochem.* 79, 311-318.
- Zhu, X., Lee, H.G., Raina, A.K., Perry, G., Smith, M.A., 2002. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. *Neurosignals* 11, 270-281.